US7419780B2 - Methods and assays for screening protein targets - Google Patents
Methods and assays for screening protein targets Download PDFInfo
- Publication number
- US7419780B2 US7419780B2 US10/705,644 US70564403A US7419780B2 US 7419780 B2 US7419780 B2 US 7419780B2 US 70564403 A US70564403 A US 70564403A US 7419780 B2 US7419780 B2 US 7419780B2
- Authority
- US
- United States
- Prior art keywords
- fusion protein
- protein
- dex
- reporter gene
- lexa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 141
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 88
- 238000012216 screening Methods 0.000 title description 30
- 238000003556 assay Methods 0.000 title description 26
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 109
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 109
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 50
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 48
- 102000004419 dihydrofolate reductase Human genes 0.000 claims abstract description 47
- 238000013518 transcription Methods 0.000 claims abstract description 47
- 230000035897 transcription Effects 0.000 claims abstract description 46
- 229960000485 methotrexate Drugs 0.000 claims abstract description 44
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 43
- 239000003446 ligand Substances 0.000 claims abstract description 32
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 230000004568 DNA-binding Effects 0.000 claims abstract description 17
- 230000001143 conditioned effect Effects 0.000 claims abstract description 5
- 239000012190 activator Substances 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 70
- 101150066555 lacZ gene Proteins 0.000 claims description 35
- 239000002299 complementary DNA Substances 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 6
- 108010001515 Galectin 4 Proteins 0.000 claims description 6
- 102100039556 Galectin-4 Human genes 0.000 claims description 6
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 74
- 102000004190 Enzymes Human genes 0.000 description 118
- 108090000790 Enzymes Proteins 0.000 description 118
- 235000018102 proteins Nutrition 0.000 description 104
- 150000001875 compounds Chemical class 0.000 description 61
- 239000000758 substrate Substances 0.000 description 50
- 238000006471 dimerization reaction Methods 0.000 description 48
- 230000000694 effects Effects 0.000 description 44
- 101001023863 Rattus norvegicus Glucocorticoid receptor Proteins 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 38
- 108020003175 receptors Proteins 0.000 description 38
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 36
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 36
- 150000003384 small molecules Chemical class 0.000 description 31
- 206010010099 Combined immunodeficiency Diseases 0.000 description 30
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 30
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 29
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 25
- 108020004256 Beta-lactamase Proteins 0.000 description 24
- 229960003957 dexamethasone Drugs 0.000 description 24
- 230000001413 cellular effect Effects 0.000 description 23
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 23
- 238000006555 catalytic reaction Methods 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 19
- 230000003197 catalytic effect Effects 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 18
- 102000012286 Chitinases Human genes 0.000 description 16
- 108010022172 Chitinases Proteins 0.000 description 16
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 16
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 16
- 238000013459 approach Methods 0.000 description 16
- 150000001782 cephems Chemical class 0.000 description 16
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 15
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 15
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 102000004157 Hydrolases Human genes 0.000 description 14
- 108090000604 Hydrolases Proteins 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 13
- 102000004357 Transferases Human genes 0.000 description 13
- 108090000992 Transferases Proteins 0.000 description 13
- 238000001360 collision-induced dissociation Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 238000010399 three-hybrid screening Methods 0.000 description 13
- 108090000364 Ligases Proteins 0.000 description 12
- 102000003960 Ligases Human genes 0.000 description 12
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000007062 hydrolysis Effects 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 12
- 108090000856 Lyases Proteins 0.000 description 11
- 102000004317 Lyases Human genes 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108010000898 Chorismate mutase Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- LHNIIDJCEODSHA-OQRUQETBSA-N (6r,7r)-3-[(e)-2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)\C=C\C=1C(=CC(=CC=1)[N+]([O-])=O)[N+]([O-])=O)C(=O)CC1=CC=CS1 LHNIIDJCEODSHA-OQRUQETBSA-N 0.000 description 7
- 229930186147 Cephalosporin Natural products 0.000 description 7
- 102000004195 Isomerases Human genes 0.000 description 7
- 108090000769 Isomerases Proteins 0.000 description 7
- 102000005936 beta-Galactosidase Human genes 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 238000010504 bond cleavage reaction Methods 0.000 description 7
- 238000006664 bond formation reaction Methods 0.000 description 7
- 229940124587 cephalosporin Drugs 0.000 description 7
- 150000001780 cephalosporins Chemical class 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 6
- 101710177451 Diels-Alderase Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- 238000001086 yeast two-hybrid system Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical group CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 241001137307 Cyprinodon variegatus Species 0.000 description 4
- 238000005698 Diels-Alder reaction Methods 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 4
- 241000588697 Enterobacter cloacae Species 0.000 description 4
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 101710100170 Unknown protein Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 150000001993 dienes Chemical class 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000012743 protein tagging Effects 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241001598984 Bromius obscurus Species 0.000 description 3
- 238000005821 Claisen rearrangement reaction Methods 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical group NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004879 Racemases and epimerases Human genes 0.000 description 3
- 108090001066 Racemases and epimerases Proteins 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000006352 cycloaddition reaction Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229930182470 glycoside Chemical group 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 238000003158 yeast two-hybrid assay Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- AUYYCJSJGJYCDS-UHFFFAOYSA-N 2/3/6893 Natural products IC1=CC(CC(N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 101100228206 Caenorhabditis elegans gly-6 gene Proteins 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 108090000175 Cis-trans-isomerases Proteins 0.000 description 2
- 102000003813 Cis-trans-isomerases Human genes 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102100030860 Exocyst complex component 3 Human genes 0.000 description 2
- 101150082479 GAL gene Proteins 0.000 description 2
- 102100028501 Galanin peptides Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000938444 Homo sapiens Exocyst complex component 3 Proteins 0.000 description 2
- 108010031311 Intramolecular Transferases Proteins 0.000 description 2
- 102000005385 Intramolecular Transferases Human genes 0.000 description 2
- 102000034335 Intramolecular lyases Human genes 0.000 description 2
- 108090000453 Intramolecular lyases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 2
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 125000000746 allylic group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- -1 cofactors Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000012750 in vivo screening Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000007149 pericyclic reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- FPWMCUPFBRFMLH-UHFFFAOYSA-N prephenic acid Chemical compound OC1C=CC(CC(=O)C(O)=O)(C(O)=O)C=C1 FPWMCUPFBRFMLH-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003161 three-hybrid assay Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 1
- GUPCXPCNUZNFEG-LWOQYNTDSA-N (6r)-4-amino-4-chloro-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound C1=CC(N)(Cl)S[C@@H]2CC(=O)N21 GUPCXPCNUZNFEG-LWOQYNTDSA-N 0.000 description 1
- 0 *OP(=O)([O-])OC.C.[H]OC.[H]OP(=O)([O-])OC Chemical compound *OP(=O)([O-])OC.C.[H]OC.[H]OP(=O)([O-])OC 0.000 description 1
- CKJCTZAIDVFHCX-UHFFFAOYSA-N 1,10-diiododecane Chemical group ICCCCCCCCCCI CKJCTZAIDVFHCX-UHFFFAOYSA-N 0.000 description 1
- IAEOYUUPFYJXHN-UHFFFAOYSA-N 1,5-diiodopentane Chemical group ICCCCCI IAEOYUUPFYJXHN-UHFFFAOYSA-N 0.000 description 1
- ZQXIMYREBUZLPM-UHFFFAOYSA-N 1-aminoethanethiol Chemical compound CC(N)S ZQXIMYREBUZLPM-UHFFFAOYSA-N 0.000 description 1
- PENWAFASUFITRC-UHFFFAOYSA-N 2-(4-chlorophenyl)imidazo[2,1-a]isoquinoline Chemical group C1=CC(Cl)=CC=C1C1=CN(C=CC=2C3=CC=CC=2)C3=N1 PENWAFASUFITRC-UHFFFAOYSA-N 0.000 description 1
- LYIVLGIYYPECGF-UBMJGTQTSA-N 2-aminoacetic acid (2S)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NCC(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O LYIVLGIYYPECGF-UBMJGTQTSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 102000001741 Acid Anhydride Hydrolases Human genes 0.000 description 1
- 108010054645 Acid Anhydride Hydrolases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- QQQLGXMDZNXBFU-SBEKHQOYSA-N C.[H]C(=O)C(O)CSCC.[H]N(CCSCC(=O)CO)C(C)=O.[H]N(CCSCC(=O)[C@@H](O)[C@H](O)[C@@H](O)CSCC)C(C)=O Chemical compound C.[H]C(=O)C(O)CSCC.[H]N(CCSCC(=O)CO)C(C)=O.[H]N(CCSCC(=O)[C@@H](O)[C@H](O)[C@@H](O)CSCC)C(C)=O QQQLGXMDZNXBFU-SBEKHQOYSA-N 0.000 description 1
- KSKDNMQJKGQGAY-UHFFFAOYSA-N C.[H]N(CC(=O)OCC(=O)N([H])CCSC)C(C)=O.[H]N(CC(C)=O)C(C)=O.[H]N(CCSC)C(=O)CC Chemical compound C.[H]N(CC(=O)OCC(=O)N([H])CCSC)C(C)=O.[H]N(CC(C)=O)C(C)=O.[H]N(CCSC)C(=O)CC KSKDNMQJKGQGAY-UHFFFAOYSA-N 0.000 description 1
- KYQHLJIBPXCYGO-UHFFFAOYSA-N CC(=O)NCCSC1C(CO)OC(C)C(O)C1O.[H]NCCCSC1CCC(C)CO1.[H]NCCCSC1CCC(OC2OC(CO)C(SCCNC(C)=O)C(O)C2O)CO1 Chemical compound CC(=O)NCCSC1C(CO)OC(C)C(O)C1O.[H]NCCCSC1CCC(C)CO1.[H]NCCCSC1CCC(OC2OC(CO)C(SCCNC(C)=O)C(O)C2O)CO1 KYQHLJIBPXCYGO-UHFFFAOYSA-N 0.000 description 1
- DSSLCMQUQHJATQ-MTCATMIHSA-K CC(=O)N[C@H](C(=O)O)[C@@H]1NC(C(=O)[O-])=C(CO)CS1.COC(=O)[C@@H](NC(C)=O)[C@@H]1NC(C(=O)[O-])=C(CSC)CS1.CS.CSCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(C)=O)[C@H]2SC1 Chemical compound CC(=O)N[C@H](C(=O)O)[C@@H]1NC(C(=O)[O-])=C(CO)CS1.COC(=O)[C@@H](NC(C)=O)[C@@H]1NC(C(=O)[O-])=C(CSC)CS1.CS.CSCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(C)=O)[C@H]2SC1 DSSLCMQUQHJATQ-MTCATMIHSA-K 0.000 description 1
- ZOWDFYOFOLNAAU-GMSGAONNSA-M CSCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(C)=O)[C@H]2SC1 Chemical compound CSCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(C)=O)[C@H]2SC1 ZOWDFYOFOLNAAU-GMSGAONNSA-M 0.000 description 1
- JGARQIYGYJMUFP-UXELSQHVSA-N C[C@H](C1)[C@@]2(C(NCCSCc3cccc(CSCC[C@@H](C(O)=O)NC(c(cc4)ccc4N(C)Cc(nc45)cnc4nc(N)nc5N)=O)c3)=O)O[C@]2(C[C@@H]2O)[C@@H]1C(CCC([C@]1(C)C=C3)=CC3=O)[C@]21F Chemical compound C[C@H](C1)[C@@]2(C(NCCSCc3cccc(CSCC[C@@H](C(O)=O)NC(c(cc4)ccc4N(C)Cc(nc45)cnc4nc(N)nc5N)=O)c3)=O)O[C@]2(C[C@@H]2O)[C@@H]1C(CCC([C@]1(C)C=C3)=CC3=O)[C@]21F JGARQIYGYJMUFP-UXELSQHVSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- IUUWIMLTJABZSQ-UHFFFAOYSA-N Cc1c(I)cc(CC(N)C(=O)O)cc1I.Oc1ccc(O)c(I)c1 Chemical compound Cc1c(I)cc(CC(N)C(=O)O)cc1I.Oc1ccc(O)c(I)c1 IUUWIMLTJABZSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000010485 C−C bond formation reaction Methods 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108010074122 Ferredoxins Proteins 0.000 description 1
- 108010057366 Flavodoxin Proteins 0.000 description 1
- 102000037909 Folate transporters Human genes 0.000 description 1
- 108091006783 Folate transporters Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 241000405147 Hermes Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100446641 Homo sapiens FKBP1A gene Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- QWOJCRAZAGPVAW-UHFFFAOYSA-N O=C(O)CCCCC1=C2NC(=O)NC2CS1 Chemical compound O=C(O)CCCCC1=C2NC(=O)NC2CS1 QWOJCRAZAGPVAW-UHFFFAOYSA-N 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 101150047747 SEC13 gene Proteins 0.000 description 1
- 101100386089 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MET17 gene Proteins 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 241001430333 Streptomyces sp. R61 Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- PQHLNKSSNYLCOV-CPDHRMHRSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCC3=CC=CC(CNC(=O)C4=CC=C(N(C)CC5=CN=C6N=C(N)N=C(N)C6=N5)C=C4)=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCC3=CC=CC(CNC(=O)C4=CC=C(N(C)CC5=CN=C6N=C(N)N=C(N)C6=N5)C=C4)=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C PQHLNKSSNYLCOV-CPDHRMHRSA-N 0.000 description 1
- VEYAJZUYMBYVAO-AHVCNKRJSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCC(=O)N[C@@H]3C(=O)N4C(C(=O)O)=C(CSCCNC(=O)CC[C@H](NC(=O)C5=CC=C(N(C)CC6=NC7=C(N=C6)N=C(N)N=C7N)C=C5)C(=O)O)CS[C@H]34)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCCC(=O)N[C@@H]3C(=O)N4C(C(=O)O)=C(CSCCNC(=O)CC[C@H](NC(=O)C5=CC=C(N(C)CC6=NC7=C(N=C6)N=C(N)N=C7N)C=C5)C(=O)O)CS[C@H]34)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCC3=CC(CSCC[C@H](NC(=O)C4=CC=C(N(C)CC5=NC6=C(N=C5)N=C(N)N=C6N)C=C4)C(=O)O)=CC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCCCCCCCCCCSCC[C@H](NC(=O)C3=CC=C(N(C)CC4=NC5=C(N=C4)N=C(N)N=C5N)C=C3)C(=O)O)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCCCCCCCCSCC[C@H](NC(=O)C3=CC=C(N(C)CC4=NC5=C(N=C4)N=C(N)N=C5N)C=C3)C(=O)O)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCC(=O)N[C@@H]3C(=O)N4C(C(=O)O)=C(CSCCNC(=O)CC[C@H](NC(=O)C5=CC=C(N(C)CC6=NC7=C(N=C6)N=C(N)N=C7N)C=C5)C(=O)O)CS[C@H]34)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCCC(=O)N[C@@H]3C(=O)N4C(C(=O)O)=C(CSCCNC(=O)CC[C@H](NC(=O)C5=CC=C(N(C)CC6=NC7=C(N=C6)N=C(N)N=C7N)C=C5)C(=O)O)CS[C@H]34)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCC3=CC(CSCC[C@H](NC(=O)C4=CC=C(N(C)CC5=NC6=C(N=C5)N=C(N)N=C6N)C=C4)C(=O)O)=CC=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCCCCCCCCCCSCC[C@H](NC(=O)C3=CC=C(N(C)CC4=NC5=C(N=C4)N=C(N)N=C5N)C=C3)C(=O)O)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C.[H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCCCCCCCCSCC[C@H](NC(=O)C3=CC=C(N(C)CC4=NC5=C(N=C4)N=C(N)N=C5N)C=C3)C(=O)O)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C VEYAJZUYMBYVAO-AHVCNKRJSA-N 0.000 description 1
- WNPVNIJRXNDFNH-BKDKTVQSSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCCCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCCCCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C WNPVNIJRXNDFNH-BKDKTVQSSA-N 0.000 description 1
- SFHVBNXZTIPZPG-MCGHEYEKSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C SFHVBNXZTIPZPG-MCGHEYEKSA-N 0.000 description 1
- RPKFHZNGXCDLLO-BKDKTVQSSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCOCCCCOCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCCOCCCCOCCCNC(=O)C3=CC=C(N(C)CC4=CN=C5N=C(N)N=C(N)C5=N4)C=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C RPKFHZNGXCDLLO-BKDKTVQSSA-N 0.000 description 1
- NIIQXMLFUPSXIK-QUUQSSQHSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCC3=CC=CC(CSCC[C@H](NC(=O)C4=CC=C(N(C)CC5=CN=C6N=C(N)N=C(N)C6=N5)C=C4)C(=O)O)=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C Chemical compound [H][C@@]12C[C@@H](C)[C@](O)(C(=O)NCCSCC3=CC=CC(CSCC[C@H](NC(=O)C4=CC=C(N(C)CC5=CN=C6N=C(N)N=C(N)C6=N5)C=C4)C(=O)O)=C3)[C@@]1(C)C[C@H](O)[C@@]1(F)C2CCC2=CC(=O)C=C[C@@]21C NIIQXMLFUPSXIK-QUUQSSQHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005365 aminothiol group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 102000028406 carbon-sulfur lyase Human genes 0.000 description 1
- 108010076637 carbon-sulfur lyase Proteins 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WTFXTQVDAKGDEY-HTQZYQBOSA-N chorismic acid Chemical compound O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005686 cross metathesis reaction Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 150000005690 diesters Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone group Chemical group [C@H]12CC[C@]3(C)[C@H](CC[C@@]3(O)C1=CC(=O)[C@@H]1C[C@@H](O)[C@@H](O)C[C@]21C)[C@H](C)[C@H](O)CCC(C)(C)O UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 102000055209 human FKBP1A Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940006292 mtx support Drugs 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- FDSSYPNUQHQSIQ-UHFFFAOYSA-N penta-2,4-dienamide Chemical compound NC(=O)C=CC=C FDSSYPNUQHQSIQ-UHFFFAOYSA-N 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 238000010916 retrosynthetic analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
Definitions
- the disclosed invention relates to the evolution of enzymes in vivo, and drug screening in vivo through the use of chemical inducers of protein dimerization.
- Combinatorial techniques allow structure-activity relationships of enzymes to be amassed quickly. With the aid of powerful selections it should be possible to create synthetically useful catalysts for pharmaceuticals and materials. However, as with proteins, it is difficult to design screens for non-protein catalysts.
- transgene expression can be regulated with tetracycline in transgenic mice highlights the utility of this system.
- ecdysone-, (No) estrogen-, (Braselman 1993) and progesterone-regulated systems (Wang 1994) have been reported.
- Molecules such as FK506 are small molecule ‘dimerizers’ (sometimes referred to as chemical inducers of dimerization, CIDs) that activate the function of numerous proteins that regulate many important cellular processes. Dimerizers allow the functions of proteins to be explored even when small molecule ligands are unknown. A limited number of such reagents have been synthesized that control the function of a much larger number of proteins (expressed as fusions of proteins of interest linked to a small molecule-responsive dimerization domain). See, e.g.
- FK506 ( FIG. 5B ) is cell permeable and has excellent pharmacokinetic properties—as evidenced by its widespread use as an immunosuppressant. FK506, however, is not an ideal chemical handle. FK506 is not available in large quantities, coupling via the C 21 allyl group requires several chemical transformations including silyl protection of FK506, (Spencer 1993, 1995, 1996; Pruschy 1994) and FK506 is both acid and base sensitive.(Wagner 1998; Coleman 1989)
- yeast three-hybrid system for detecting ligand-receptor interactions in vivo.
- This system is based on the principle that small ligand-receptor interactions underlie many fundamental processes in biology and form the basis for pharmacological intervention of human diseases in medicine.
- This system is adapted from the yeast two-hybrid system by adding a third synthetic hybrid ligand. The feasibility of this system was demonstrated using as the hybrid ligand a dimer of covalently linked dexamethasone and FK506.
- the system used yeast expressing fusion proteins consisting of a) hormone binding domain of the rat glucocorticoid receptor fused to the LexA DNA-binding domain and b) FKBP12 fused to a transcriptional activation domain.
- the reporter genes were activated.
- the reporter gene activation is completely abrogated in a competitive manner by the presence of excess FK506.
- a screen was performed of a Jurkat cDNA library fused to the transcriptional activation domain in yeast in the presence of a methasone-FK506 heterodimer.
- the yeast in this system expressed the hormone binding domain of rat glucocorticoid receptor/DNA binding domain fusion protein. Overlapping clones of human FKBP12 were isolated. These results demonstrate that the three-hybrid system can be used to discover receptors for small ligands and to screen for new ligands to known receptors.
- WO 96/30540 discloses a screen for ⁇ -lactamase activity that uses fluorescence resonance energy transfer as the indicator of ⁇ -lactamase activity.
- the degree of fluorescence in this screen depends on the level of ⁇ -lactamase activity. Detection of ⁇ -lactamase activity relies on detection of changes in the degree of fluorescence.
- This invention provides proteins de novo with prescribed binding and catalytic properties and permits screening cDNA libraries based on biochemical function. Being able to understand and manipulate protein-small molecule interactions has broad implications for basic biomedical research and the pharmaceutical industry. Proteins engineered to have unique binding or catalytic properties have already proven useful as biomedical reagents, medical diagnostics, and even therapeutics. As with site-directed mutagenesis before it, randomization and screening techniques also offer an entirely new approach to understanding the molecular basis for recognition and catalysis. Technically, a high-throughput approach such as that disclosed here would speed-up the research because the activity of thousands of protein variants can be measured simultaneously.
- a powerful screen is also critical to the end goal of genome sequencing efforts-determining the function of each and every protein, bypassing decades of detailed biochemical and genetic experiments to unravel complex biochemical pathways. Since the screen is done in vivo and in both prokaryotes and eukaryotes, the methodology can be applied to functional genomics and drug discovery.
- a cDNA library can be screened for all enzymes that form or cleave a specific type of bond.
- a library of small molecules can be screened for its ability to inhibit a specific enzyme.
- the screen selects for cell permeability, compatibility with the cellular milieu, and inhibition of enzyme activity.
- the key to all of these applications is a robust screen for enzymatic activity such as that disclosed here.
- the subject invention provides a compound having the formula: H1-X-B-Y-H2 wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety.
- This invention also provides a method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:
- FIG. 1 The selection strategy. Proteins V and W do not interact (A) until a BOND links the handles H1 and H2 (B).
- the selection can be run in the forward direction to select for BOND formation or the reverse direction to select for BOND cleavage.
- FIG. 2 The yeast three-hybrid system.
- the small molecule dexamethasone-FK506 (H1-H2) mediates the dimerization of the LexA-GR (glucocorticoid receptor) and B42-FKBP12 protein fusions. Dimerization of the DNA-binding protein LexA and the activation domain B42 activates transcription of the lacZ reporter gene.
- FIG. 3 The Model reaction. Cephalosporin hydrolysis by the 908R cephalosporinase.
- FIG. 4 DEX-CEPHEM-FK506 retrosynthesis. Cephem 1 is commercially available. DEX-CO 2 H is prepared via oxidation of the C 20 ⁇ -hydroxy ketone; FK506-CO 2 H, via a cross-metathesis reaction with the C 23 allyl group.
- FIG. 5 The chemical handles dexamethasone (A), FK506 (B), and methotrexate (C).
- FIG. 6 The dexamethasone-methotrexate molecules synthesized.
- the diamine linkers are commercially available and vary in length and hydrophobicity.
- FIG. 7 The Claisen rearrangement (A) and the Diels-Alder reaction (B) are both pericyclic reactions with six-membered transition states.
- FIG. 8 The retro-synthesis of the diene (A) and the dienophile (B).
- a Curtius rearrangement is used to introduce the carbamyl linkage to H1 in the diene.
- a Stille coupling is used to introduce the alkyl linkage to H2 in the dienophile.
- the cyclohexene product will be prepared through the cycloaddition of these two compounds.
- FIG. 9 Examples of DEX-DEX molecules synthesized to date.
- FIG. 10 DEX-MTX retrosynthesis.
- FIG. 11 Maps of the plasmids encoding the LexA-GR and B42-GR fusion proteins.
- FIG. 12 Dex-cephem-Mtx retro-synthesis.
- FIG. 13 Dex-Mtx protein dimerization system.
- a cell-permeable Dex-Mtx molecule is used to induce dimerization of LexA-GR and DHFR-B42 protein chimeras, activating transcription of a lacZ reporter gene.
- FIG. 14 Cell based assays. Yeast cells containing LexA-GR and B42-DHFR fusion proteins and the lacZ reporter gene are grown on X-gal plates with or without Dex-Mtx. Dex-Mtx dimerizes the fusion proteins, activating lacZ transcripiton, hydrolyzing the chromogenic substrate X-gal, and turning the cells blue. Dex-Mtx is added directly to the media in the x-gal plate. The assay takes two to five days.
- FIG. 15 X-gal plate assay of Dex-cephem-Mtx induced lacZ transcription.
- the strains that are dark (blue in original) even in the absence of small molecule (plate C) are positive controls on protein-protein interaction.
- the dark strains on plates A and B express LexA DHFR and B42-GR fusion proteins, and the white strains are negative controls, expressing only LexA and B42.
- FIG. 16A Plate BTC4 grown on 4 different plates after 72 hours. One plate has no small molecule, so just the positive controls should be dark. The other three plates all have either 10 uM DM1, 10 uM D8M, or 10 uM D10M.
- FIG. 16B is the plate map for plate BTC4.
- FIG. 17A Plate BTC6 grown on 4 plates after 56 hours. Twotop plates contain no small molecule, and the bottom two plates contain 10 uM D10M.
- FIG. 17B shows plate BTC6 grown on 2 plates after 60 hours. Both plates contain 1 uM D8M.
- FIG. 17C shows the plate map for plate BTC6.
- FIG. 18 The ⁇ -galactosidase activity of strain V494Y using varying concentrations of D8M.
- FIG. 19 A screen for glycosidase activity.
- Dex-Mtx CIDs with cleavable oligosaccharide linkers used to assay the >3000 proteins in S. cerevisiae of unknown function for glycosidase activity.
- a yeast cDNA library is introduced into the selection strain. Only cells expressing active glycosidases cleave the oligosaccharide linker, disrupt ura3 transcription, and survive in the presence of 5-FOA.
- FIG. 20 Proposed solid-phase synthesis of the Dex-Mtx glycosidase substrates. While the synthesis of Dex-(GlcNAc) 4 -Mtx is shown, the synthesis is designed to allow the introduction of a variety of sugar monomers with both regio- and stereo-control.
- the subject invention provides a compound having the formula: H1-X-B-Y-H2 wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety.
- each of H1 and H2 is capable of binding to a receptor with a IC 50 of less than 100 nM. In a preferred embodiment, each of H1 and H2 is capable of binding to a receptor with a IC 50 of less than 10 nM. In the most preferred embodiment, each of H1 and H2 is capable of binding to a receptor with a IC 50 of less than 1 nM.
- B is capable of binding to an enzyme with an IC 50 of less than 100 mM. In a further embodiment, B is capable of binding to an enzyme with an IC 50 of less than 10 mM. In yet a further embodiment, B is capable of binding to an enzyme with an IC 50 of less than 1 mM. In a preferred embodiment, B is capable of binding to an enzyme with an IC 50 of less than 100 ⁇ M, more preferably, B is capable of binding to an enzyme with an IC 50 of less than 10 ⁇ M, and most preferably, B is capable of binding to an enzyme with an IC 50 of less than 1 ⁇ M.
- either of H1 and H2 are different, or X and Y are different.
- B may be cleavable by an enzyme selected from the group of enzymes consisting of transferases, hydrolases, lyases, isomerases, and ligases.
- the transferase is selected from the group consisting of, a one carbon transferase, an aldehyde or ketone transferase, an acyl transferase, a glycosyl transferase, an alkyl or aryl trasferase, a N-containing group transferase, a P-containing group transferase, an S-containing group transferase, an O-containing group, and a Se-containing group transferase.
- the hydrolase is selected from the group consisting of an ester hydrolase, a glycosidic hydrolase, an ether hydrolase, a peptide hydrolase, a C—N (non-peptide) hydrolase, an acid anhydride hydrolase, a C—C hydrolase, a P—N hydrolase, an S—N hydrolase, a C—P hydrolase, and an S—S hydrolase.
- the lyase is selected from the group consisting of a C—C lyase, a C—O lyase, a C—N lyase, a C—S lyase, and a P—O lyase.
- the isomerase is selected from the group consisting of racemases, epimerases, cis-trans isomerases, intra-oxidoreductases, intra-transferases (mutases), and intramolecular lyases.
- the ligase is selected from the group consisting of a C—O ligase, a C—S ligase, a C—N ligase, a C—C ligase, and a P—O ligase.
- B is an enzyme cleavable moiety selected from the group consisting of phosphodiester, glycoside, amide, ester, diester, aldol product, and acetate moiety. In a most preferred embodiment B represents an amide moiety, or a cephem moiety.
- H1 or H2 may be derived from a compound selected from the group consisting of steroids, hormones, nuclear receptor ligands, cofactors, antibiotics, sugars, enzyme inhibitors, and drugs.
- H1 and H2 may also represent a compound selected from the group consisting of dexamethasone, 3,5,3′-triiodothyronine, trans-retinoic acid, biotin, coumermycin, tetracycline, lactose, methotrexate, FK506, and FK506 analogs.
- each of H1 and H2 is derived from the compound of FIG. 5A , or the compound of FIG. 5B , or the compound of FIG. 5C .
- the compound H1-X-B-Y-H2 may be formed in a cell the reaction of a first compound having the formula: H1-X-B′ with a second compound having the formula: H2-Y-B′′ wherein B′ and B′′ are moieties that react to form B in the presence of an enzyme.
- the enzyme in this reaction may be selected from the group of enzymes consisting of transferases, lyases, isomerases, and ligases.
- Each one of the transferases, lyases, isomerases, and ligases comprises groups as noted above.
- This invention also provides a compound having the formula: H1-X-B′ wherein H1 is capable of binding to a receptor; wherein X is a spacer moiety which may be present or absent; and wherein B′ is a moiety capable of binding to an enzyme.
- H1 should be capable of binding to a receptor with a IC 50 of less than 100 nM, preferably H1 is capable of binding to a receptor with a IC 50 of less than 10 nM, more preferably H1 is capable of binding to a receptor with a IC 50 of less than 1 nM.
- B′ should be capable of binding to an enzyme with an IC 50 of less than 100 mM, preferably B′ is capable of binding to an enzyme with an IC 50 of less than 50 mM, more preferably B′ is capable of binding to an enzyme with an IC 50 of less than 1 mM, yet more preferably B′ is capable of binding to an enzyme with an IC 50 of less than 100 ⁇ M, yet more preferably B′ is capable of binding to an enzyme with an IC 50 of less than 10 ⁇ M, and most preferably B′ is capable of binding to an enzyme with an IC 50 of less than 1 ⁇ M.
- the compound H1-X-B′ may react with a moiety which has the formula: H2-Y-B′′ wherein H2 is capable of binding to a receptor; wherein Y is a spacer moiety which may be present or absent; wherein B′′ is a moiety that reacts with B′ in the presence of the enzyme.
- This invention also provides a complex comprising the compound having the formula H1-X-B-Y-H2 complexed to an enzyme.
- the compound is capable of binding to the enzyme with an IC 50 of less than 100 mM, preferably with an IC 50 of less than 10 mM, more preferably with an IC 50 of less than 1 mM, yet more preferably with an IC 50 of less than 100 ⁇ M, yet more preferably with an IC 50 of less than 10 ⁇ M, and most preferably with an IC 50 of less than 1 ⁇ M.
- This invention also provides a complex comprising the compound having the formula H1-X-B′ complexed to an enzyme.
- the compound is capable of binding to the enzyme with an IC 50 of less than 100 mM, preferably with an IC 50 of less than 10 mM, more preferably with an IC 50 of less than 1 mM, yet more preferably with an IC 50 of less than 100 ⁇ M, yet more preferably with an IC 50 of less than 10 ⁇ M, and most preferably with an IC 50 of less than 1 ⁇ M.
- This invention also provides a composition comprising the compound having the formula H1-X-B-Y-H2, or the compound having the formula H1-X-B′.
- the composition may further comprise an enzyme.
- This invention also provides a composition comprising the complex of the compound having the formula H1-X-B-Y-H2 with an enzyme, or of the compound having the formula H1-X-B′ with an enzyme.
- This invention also provides a method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:
- the cellular readout may be reconstitution of enzymatic activity.
- the method further provides a cell that contains a gene which is activated by a dimerized pair of fusion proteins.
- the pair of fusion proteins are dimerized by a compound having the formula H1-X-B-Y-H2.
- the cellular readout may also be gene transcription, such that a decrease of gene transcription indicates catalysis of bond cleavage by the protein to be screened.
- the gene transcribed may be lacZ, leu2, ura3, his3, or trp.
- This invention also provides a method of screening proteins for the ability to catalyze bond formation, comprising the steps of:
- the cellular readout may be enzyme activity.
- the method further comprises providing a cell that contains a gene which is activated by the dimerized pair of fusion proteins.
- the cellular readout may be gene transcription, such that an increase in gene transcription indicates catalysis of bond formation by the protein to be screened.
- either the first or the second compound is the compound having the formula H1-X-B′.
- the cell is selected from the group consisting of yeast, bacteria or mammalian.
- the cell may be selected from the group consisting of S. cerevisiae , and E. coli.
- the pair of fusion proteins is the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to LexA, and FKBP12 fused to the B42 transcriptional activation domain.
- rGR2 rat glucocorticoid receptor
- the pair of fusion proteins may also be the dihydrofolate reductase (DHFR), or binding domain thereof, fused to LexA, and FKBP12 fused to the B42 transcriptional activation domain.
- DHFR dihydrofolate reductase
- the pair of fusion proteins may further be dihydrofolate reductase (DHFR), or binding domain thereof, fused to LexA, and the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to the B42 transcriptional activation domain.
- DHFR dihydrofolate reductase
- rGR2 rat glucocorticoid receptor
- the pair of fusion proteins may yet further be the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused to LexA, and dihydrofolate reductase (DHFR), or binding domain thereof, fused to the B42 transcriptional activation domain.
- rGR2 rat glucocorticoid receptor
- DHFR dihydrofolate reductase
- the pair of fusion proteins may yet even further be dihydrofolate reductase (DHFR), or binding domain thereof, fused to LexA, and the rat glucocorticoid receptor (rGR2), or binding domain thereof, fused through a 6-Glycine linker to the B42 transcriptional activation domain.
- DHFR dihydrofolate reductase
- rGR2 rat glucocorticoid receptor
- the protein to be screened is an enzyme selected from the group of enzyme classes consisting of transferases, hydrolases, lyases, isomerases and ligases.
- the screening is performed by Fluorescence Associated Cell Sorting (FACS), or gene transcription markers selected from the group consisting of Green Fluorescence Protein, LacZ- ⁇ -galagctosidases, luciferase, antibiotic resistant ⁇ -lactamases, and yeast markers.
- FACS Fluorescence Associated Cell Sorting
- This invention also provides a method of screening a compound for the ability to inhibit an enzyme comprising:
- This invention also provides a drug for the inhibition of an enzyme selected by this method.
- This invention further provides a method of evolving a protein with a new catalytic activity comprising screening proteins derived from a library of proteins which are mutants of a known protein, using either of the screening methods provided by this invention.
- this invention also provides a protein with new catalytic activity evolved by this method.
- This invention also provides a method of evolving an enzyme with a new substrate specificity comprising screening enzymes derived from a library of enzymes which are mutants of an enzyme with known substrate specificity, using either of the screening methods provided by this invention.
- this invention provides an engineered enzyme having new substrate specificity evolved by this method.
- This invention also provides a method for evolving an enzyme that functions with a cofactor which is different from the cofactor the natural coenzyme uses, comprising:
- this invention provides an engineered enzyme that functions with a cofactor which is different from cofactors the enzymes naturally uses evolved by this method.
- H1-Y-H2 wherein H1 is methorexate or an analog thereof; wherein H2 is capable of binding to a receptor, and wherein Y is a moiety providing a covalent linkage between H1 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2.
- H2 may be Dex or an analog thereof.
- H1 is Mtx, then H2 may be Dex or an analog thereof.
- the compound may also have the formula Mtx-Y-H2, and the formula Dex-Y-Mtx.
- the compound may also have the formula:
- H2 may be capable of binding to a receptor with an IC50 of less than 100 mM; or an IC50 of less than 10 mM; or an IC50 of less than 1 mM; or an IC50 of less than 100 ⁇ M; or an IC50 of less than 10 ⁇ M; or an IC50 of less than 1 ⁇ M; or an IC50 of less than 100 nM; or an IC50 of less than 10 nM; or an IC50 of less than 1 nM.
- the compound may have the formula:
- the compound may also have the formula:
- the compound may also have the formula:
- the compound may also have the formula:
- the compound may also have the formula:
- the binding domain may be that of the DHFR receptor.
- H1 is capable of binding to the binding domain of the fusion protein with an IC50 of less than 100 nM; or an IC50 of less than 10 nM; or an IC50 of less than 1 nM; or an IC50 of less than 100 pM; or an IC50 of less than 10 pM; or an IC50 of less than 1 pM.
- the fusion protein may be DHFR-LexA, or DHFR-B42.
- the first fusion protein or the second fusion protein may be DHFR-(DNA-binding domain); or the first fusion protein or the second fusion protein may be DHFR-(transcription activation domain).
- the first fusion protein or the second fusion protein may be DHFR-LexA; or first fusion protein or the second fusion protein is DHFR-B42.
- the cell may be selected from the group consisting of insect cells, yeast cells, mammalian cell, and their lysates.
- the first or the second fusion protein may comprise a transcription module selected from the group consisting of a DNA binding protein and a transcriptional activator.
- the molecule may be obtained from a combinatorial library.
- Steps (b)-(e) of the method may be repeated iteratively in the presence of a preparation of random small molecules for competitive binding with the hybrid ligand so as to identify a molecule capable of competitively binding the known target.
- the unknown protein target may be encoded by a DNA from the group consisting of genomic DNA, cDNA and synthetic DNA.
- the ligand may have a known biological function.
- the selection strategy is based on existing methods for controlling protein dimerization in vivo using small molecules ( FIG. 1 ).
- Several “chemical inducers of dimerization” have been reported showing that protein dimerization can be bridged by small molecules.
- Spencer 1996, 1995, 1993; Crabtree 1996)
- a number of techniques exist for translating the dimerization of two proteins to an in vivo screen or selection. Human 1990; Hu 1995; Fields 1989; Gyuris 1993; Johnsson 1994; Rossi 1997; Karimova 1998)
- this work establishes that it is feasible to use a small molecule H1-H2 to dimerize two fusion proteins, reporter V-H1 receptor and reporter W-H2 receptor, generating a cellular read-out.
- H1 and H2 Disclosed is the dimerization of two proteins via covalent coupling of H1 and H2 as the basis for a general selection for catalysis. That is, the small-molecule H1-X-BOND-Y-H2 represented in FIG. 1 is used to mediate protein dimerization and hence a cellular signal. Then the enzyme that catalyzes either BOND formation or BOND cleavage is selected. The catalyst is tied to the cellular “read-out” because only cells containing an active enzyme have the desired phenotype.
- the strategy is both general and a direct selection for catalysis.
- the selection can be applied to a broad range of reactions because protein dimerization depends only on H1 and H2, not X, Y, or the BOND being formed or cleaved. It is a direct selection for catalysis because covalent coupling of H1 and H2 is necessary for protein dimerization. Also, unlike catalytic antibodies, this strategy does not limit the starting protein scaffold.
- a chemical handle should bind its receptor with high affinity ( ⁇ 100 nM), cross cell membranes yet be inert to modification or degradation, be available in reasonable quantities, and present a convenient side-chain for routine chemical derivatization that does not disrupt receptor binding.
- DEX-FK506 H1-H2
- B42-FKBP12 FIG. 2
- Dexamethasone is a very attractive chemical handle H1 ( FIG. 5A ).
- DEX binds rat glucocorticoid receptor (GR) with a K D of 5 nM, (Chakraborti 1991) can regulate the in vivo activity and nuclear localization of GR fusion proteins (Picard 1987), and is commercially available. Affinity columns for rGR have been prepared via the C 20 ⁇ -hydroxy ketone of dexamethasone. (Govindan 1980; Manz 1983)
- the antibacterial and anticancer drug methotrexate (MTX) is used in place of FK506 as the chemical handle H2 ( FIGS. 5B , 5 C).
- FK506 is not available in large quantities, coupling via the C 21 allyl group requires several chemical transformations including silyl protection of FK506, (Spencer 1993, 1995, 1996; Pruschy 1994) and FK506 is both acid and base-sensitive. (Wagner 1995, 1998; Coleman 1989) MTX, on the other hand, is commercially available and can be modified selectively at its ⁇ -carboxylate without disrupting dihydrofolate reductase (DHFR) binding.
- DHFR dihydrofolate reductase
- DEX-MTX ability of DEX-MTX to mediate the dimerization of LexA-rGR and B42-DHFR is tested by (1) synthesis of a series of DEX-MTX molecules with simple diamine linkers ( FIG. 6 ); and (2) showing that DEX-MTX can dimerize LexA-rGR and B42-DHFR based on lacZ transcription and that both DEX and MTX uncoupled, can, competitively disrupt this dimerization.
- Cell permeable chemical handles that can be prepared readily and that are efficient at inducing protein dimerization not only are essential to the robustness of this selection methodology but also should find broad use as chemical inducers of protein dimerization.
- Dexamethasone and the glucocorticoid receptor (GR) present a particularly attractive chemical handle/receptor pair.
- Dexamethasone is the cortical steroid with the highest affinity for the rat Glucocorticoid Receptor.
- the rGR binds DEX with a K D of 5 nM, and mutants of rGR have been isolated with up to 10-fold higher affinity for DEX. (Chakraborti 1991)
- the steroid dexamethasone has been used extensively as a cell-permeable small molecule to regulate the in vivo activity and nuclear localization of GR fusion proteins.
- Methotrexate (MTX) inhibition of dihydrofolate reductase (DHFR) is one of the textbook examples of high-affinity ligand binding.
- MTX dihydrofolate reductase
- DHFR dihydrofolate reductase
- MTX is known to be imported into cells via a specific folate transporter protein. MTX is commercially available and can be synthesized readily from simple precursors. MTX can be modified selectively at its g-carboxylate without disrupting its interaction with DHFR. (Kralovec 1989, Bolin 1982) There are several examples reported where MTX has been modified via its g-carboxylate to prepare affinity columns and antibody conjugates.
- Other handles H1 and H2 may be for example, steroids, such as the Dexamethasone used herein; enzyme inhibitors, such as Methotrexate used herein; drugs, such as KF506; hormones, such as the thyroid hormone 3,5,3′-triiodothyronine (structure below)
- Ligands for nuclear receptors such as retinoic acids, for example the structure below
- antibiotics such as Coumermycin (which can be used to induce protein dimerization according to Perlmutter et al., Nature 383, 178 (1996)).
- Mtx and the DHFR receptor present a particularly attractive chemical handle/receptor pair.
- the complex of an Mtx moiety and the DHFR binding domain is extremely well characterized.
- the excellent pharmacokinetic properties of Mtx make it an ideal moiety to be used in procedures where ease of importation into cells is required.
- FIG. 9 To illustrate how the handles H1 and H2 may be linked together, several of the DEX-DEX compounds that have been synthesized to date are shown in FIG. 9 .
- the linkers are all commercially available or can be prepared in a single step. The linkers vary in hydrophobicity, length, and flexibility.
- a series of DEX-DEX molecules have been synthesized ( FIG. 9 ).
- the DEX-DEX molecules shown in FIG. 9 were prepared from Dexamethasone and the corresponding diamines.
- the C 20 a-hydroxy ketone of dexamethasone was oxidized using sodium periodate to the corresponding carboxylic acid in quantitative yield as described.
- the diamines are commercially available.
- the diamine corresponding to DEX-DEX 2 was prepared from a,a′-dibromo-m-xylene and aminoethanethiol and used crude.
- the diamines were coupled to the carboxylic acid derivative of dexamethasone using the peptide-coupling reagent PyBOP under standard conditions in 60-80% yield.
- the retrosynthesis is shown in FIG. 10 .
- the synthesis is designed to be modular so that we can easily bring in a variety of linkers in one of the final steps as the dibromo- or diiodo-derivatives.
- the glutamate residue has been replaced with homocysteine. This replacement should be neutral because there is both biochemical and structural evidence that the g-carboxylate of methotrexate can be modified without disrupting DHFR binding.
- the final compound has been synthesized in 12 steps in 1.3% overall yield.
- the second important feature is the design of the protein chimeras.
- the yeast two-hybrid assay was chosen in the examples because of its flexibility. Specifically, the Brent two-hybrid system is used, which uses LexA as the DNA-binding domain and B42 as the transcription activation domain. The Brent system is one of the two most commonly used yeast two-hybrid systems.
- LexA- and B42-receptor fusions are facilitated by the availability of commercial vectors for the Brent two-hybrid system. These vectors are shuttle vectors that can be manipulated both in bacteria and yeast.
- the LexA chimera is under control of the strong, constitutive alcohol dehydrogenase promoter.
- the B42 chimera is under control of the strong, regulatable galactose promoter.
- Both the GR and the two DHFR genes were introduced into the multiple cloning sites of the commercial LexA and B42 expression vectors using standard molecular biology techniques.
- the GR fusions are shown in FIG. 11 .
- the available restriction sites result in a three amino acid spacer between the two proteins in both the GR and the DHFR constructs.
- the plasmids encoding the LexA- and B42-fusion proteins were introduced in all necessary combinations into S. cerevisiae strain FY250 containing a plasmid encoding the lacZ reporter plasmid.
- Three initial assays are conducted: (1) toxicity of the ligand and receptor, (2) cell permeability of the H1-H2 molecules as judged by competition in the yeast three-hybrid system, and (3) activation of lacZ transcription by the H1-H2 molecule as judged by X-gal hydrolysis. All of these experiments have been done as plate assays. The toxicity of the ligand and receptor is judged simply by seeing if either induction of the receptor fusions or application of the ligand to the plate impairs cell growth. Cell permeability is assessed based on the ability of an excess of DEX-DEX or DEX-MTX to disrupt DEX-FK506 induction of lacZ transcription in the yeast three-hybrid system.
- DEX-DEX or DEX-MTX should bind to all of the available LexA-GR chimera and disrupt transcription activation so long as the molecule is cell permeable and retains the ability to bind to GR. Effective protein dimerization by H1-H2 is assayed by activation of lacZ transcription.
- DEX-DEX 1 and DEX-DEX 5 have been assayed for cell permeability. At 1 ⁇ M DEX-FK506 and 10 ⁇ M DEX-DEX, DEX-DEX 1, but not DEX-DEX 5, decreases lacZ transcription in the yeast three-hybrid system by 50%.
- the protein chimeras can be varied in four ways: (1) invert the orientation of the B42 activation domain and the receptor; (2) introduce tandem repeats of the receptor; (3) introduce (GlyGlySer) n linkers between the protein domains; (4) vary the DNA-binding domain and the transcription activation domain.
- inverting the orientation so that the receptor, not B42, is N-terminal is trivial.
- linkers may be designed according to the type of enzymatic activity desired.
- the linkers are readily synthesized by known techniques. For example, the following linkers may be used:
- the subject invention can screen derivatives of a large classes of enzymes.
- E.C. Enzyme Commission
- oxidoreductases are, for example:
- the subclasses of transferases are, for example:
- hydrolases are, for example:
- the subclasses of lyases are, for example:
- the subclasses of isomerase are, for example:
- ligases are, for example:
- Each of the mentioned classes is further separated into sub, sub-classes, i.e. the “c” level, and then the “d” level.
- a reporter gene assay measures the activity of a gene's promoter. It takes advantage of molecular biology techniques, which allow one to put heterologous genes under the control of a mammalian cell (Gorman, C. M. et al., Mol. Cell Biol. 2: 1044-1051 (1982); Alam, J. And Cook, J. L., Anal. Biochem. 188: 245-254, (1990)). Activation of the promoter induces the reporter gene as well as or instead of the endogenous gene. By design the reporter gene codes for a protein that can easily be detected and measured. Commonly it is an enzyme that converts a commercially available substrate into a product. This conversion is conveniently followed by either chromatography or direct optical measurement and allows for the quantification of the amount of enzyme produced.
- Reporter genes are commercially available on a variety of plasmids for the study of gene regulation in a large variety of organisms (Alam and Cook, supra). Promoters of interest can be inserted into multiple cloning sites provided for this purpose in front of the reporter gene on the plasmid (Rosenthal, N., Methods Enzymo. 152: 704-720 (1987); Shiau, A. and Smith, J. M., Gene 67: 295-299 (1988)). Standard techniques are used to introduce these genes into a cell type or whole organism (e.g., as described in Sambrook, J., Fritsch, E. F. and Maniatis, T. Expression of cloned genes in cultured mammalian cells. In: Molecular Cloning , edited by Nolan, C. New York: Cold Spring Harbor Laboratory Press, 1989). Resistance markers provided on the plasmid can then be used to select for successfully transfected cells.
- the reporter gene under the control of the promoter of interest is transfected into cells, either transiently or stably.
- Receptor activation leads to a change in enzyme levels via transcriptional and translational events.
- the amount of enzyme present can be measured via its enzymatic action on a substrate.
- the host cell for the foregoing screen may be any cell capable of expressing the protein or cDNA library of proteins to be screened.
- Some suitable host cells have been found to be yeast cells, Saccharomyces Cerevisiae , and E. Coli.
- Dex-Mtx can dimerize a LexA-DHFR and a B42-rGR protein chimera in vivo (Table I). (Lin, 2000) Dex-Mtx was assayed using both plate and liquid assays at extracellular concentrations of 1-100 ⁇ M. No activation was observed at concentrations ⁇ 0.1 ⁇ M. 100 ⁇ M is the limit of Dex-Mtx solubility. Control experiments established that lacZ transcription is dependent on Dex-Mtx. There are only background levels of lacZ transcription when Dex-Mtx is omitted, LexA-DHFR is replaced with LexA, or B42-GR is replaced with B42.
- the subject invention is exemplified using the components of the yeast three-hybrid system (Licitra, represented in FIG. 2 , see also U.S. Pat. No. 5,928,868).
- DEX-FK506 exemplifying H1-H2
- H1-H2 mediates dimerization of the protein fusions LexA-GR (representing reporter V-H1 receptor) and B42-FKBP12 (representing reporter W-H2 receptor) thus activating transcription of a lacZ reporter gene.
- the chemical handles H1 and H2 and the protein dimerization assay, however, all can be varied.
- the yeast three-hybrid system is altered by inserting a BOND, B, as well as any required spacers X and Y, so as to form a small molecule having the structure H1-X-B-Y-H2. While there is ample precedent for small-molecule mediated protein dimerization, what remains is to show these assays can be used to select for catalysts.
- Cephalosporin hydrolysis by a cephalosporinase provides a simple cleavage reaction to demonstrate the selection ( FIG. 3 ).
- the BOND, B in this example is cephem linkage susceptible to attack by caphalosporinase, such that hydrolysis of the cephalosporinase results in separation of the proteins and deactivation of the transcription of lacZ.
- the E. cloacae 908R cephalosporinase is well characterized both biochemically (Galleni 1988(a); Galleni 1988(b); Galleni 1988(c); Monnaie 1992) and structurally (Lobkovsky 1993) and is simple to manipulate.
- Several approaches have been developed for modifying cephalosporin antibiotics at the C7′ and C3′ positions to improve their pharmacokinetic properties and to prepare pro-drugs. (Druckheimer 1988; Albrecht 1990; Vrudhula 1995; Meyer 1995)
- Cephalosporin hydrolysis by the cephalosporinase can disrupt protein dimerization and hence be used to discriminate between cells containing active and inactive enzyme.
- (1) (C.)DEX-CEPHEM-(C3′)FK506 is synthesized; (2) DEX-CEPHEM-FK506 is shown to dimerize LexA-GR and B42-FKBP12 and both DEX and FK506 is shown to disrupt the dimerization; (3) induction of the wild type cephalosporinase, but not an inactive Ser 64 variant, is shown to disrupt cephem-mediated protein dimerization; and (4) cells containing active cephalosporinase are identified based on loss of protein dimerization in a mock screen. A screen for loss of lacZ transcription is sufficient for the screen.
- the retro-synthesis of DEX-CEPHEM-FK506 is shown in FIG. 4 ; it allows H1, H2, and the linker molecules to be varied.
- the allelic chloride intermediate 2 has been synthesized from cephem 1 in 20% yield in four steps. Mild conditions for coupling H2-SH to the allelic chloride 2 using sodium iodide have been developed; DEX-SH can be coupled in 82% yield.
- 908R cephalosporinase variants have been constructed both with and without nuclear-localization sequences under control of GAL1 and MET25 promoters. All of these variants are known to be active in vivo by using the chromogenic substrate nitrocefin, (Pluckthun 1987).
- S. cerevisiae strains suitable for this model reaction have been constructed.
- DEX-FK506 is know to dimerize LexA-rGR and B42-FKBP12 in these strain backgrounds (yeast three-hybrid system).
- strain FY250/pMW106/pMW2rGR2/pMW3FKBP12 We have constructed strain FY250/pMW106/pMW2rGR2/pMW3FKBP12 and shown that Dex-FK506 can still mediate dimerization of LexA-rGR and B42-FKBP12 in this strain.
- the strain provides an additional marker for the enzyme, grows well on galactose and raffinose, and replaces all of the amp R markers with kan R or spec R markers.
- galactose- or methionine-regulated overexpression of the cephalosporinase Based on hydrolysis of the chromagenic substrate nitrocefin, (Pluckthun, 1987) we have shown that the cephalosporinase is active in the FY250 background.
- the cephem substrates were designed such that introduction of the Dex and Mtx ligands would not interfere with cephalosporinase hydrolysis of the cephem core and so that a variety of Dex-cephem-Mtx substrates could be synthesized readily from commercially available materials.
- the chemistry of the b - lactams ; Durckheimer 1988; Albrecht 1990; Meyer 1995; Zlokarnik 1998) We synthesized four potential Dex-cephem-Mtx substrates from a commercial amino-chloro-cephem intermediate.
- Dexamethasone was coupled to the C7 amino group of the cephem core via aminocarboxylic acids of different lengths, and methotrexate to the C3′ chloro group via aminothiols of different lengths. All four compounds were prepared from three components in 3-4 steps in 10-30% overall yield.
- the next step is to demonstrate that the screen can discriminate between active and inactive enzymes.
- the penicillin-binding protein (PBP) from Streptomyces R61 provides a good control “inactive” enzyme to compare to the active Q908R cephalosporinase.
- PBP penicillin-binding protein
- Cephalosporinases are believed to have evolved from PBPs.(Ghuysen 1991; Knox 1996) Both enzymes have the same three-dimensional fold and follow the same catalytic mechanism involving an acyl-enzyme intermediate.
- the Dex-cephem-Mtx CID screen distinguish between the cephalosporinase and the PBP. Yeast strains containing the cephalosporinase hydrolyze the cephem linkage rapidly, disrupting lacZ transcription. The PBP, on the other hand, hydrolyze the cephem linkage too slowly to change the levels of lacZ transcription significantly.
- the Brent Y2H vectors currently employed in the lab will have to be modified to allow for control over the levels and timing of LexA- and B42-expression.
- the Brent vectors have the LexA fusion protein under control of the strong, constitutive alcohol dehydrogenase promoter (P ADH ) and the B42 fusion protein under control of the strong galactose-inducible promoter (P GAL ).
- Both vectors contain the high-copy yeast 2 ⁇ origin of replication.
- the GAL promoter is the most tightly regulated promoter available in yeast and is induced by galactose and repressed by glucose.
- the sensitivity of the system can be tuned by varying the substrate:product ratio by adding both Dex-cephem-Mtx (substrate) and Dex and Mtx (“product”) to the growth media.
- coli K12 AmpC b-lactamase (71% homologous) are available spanning a wide range of k cat , K m , and k cat /K m values (Table II).
- kinetic rate constants for the corresponding Q908R cephase variants with the Dex-cephem-Mtx and ampicillin substrates and nitrocefin as a control.
- the Q908R cephase variants will be constructed in the E. coli expression vector by site-directed mutagenesis, using a PCR-based method. These proteins will then be purified by nickel-affinity chromatography, and rate constants will be determined by UV spectroscopy, monitoring the disappearance of absorbance due to the b-lactam bond.
- the mutants After determining the activity of the mutants with Dex-cephem-Mtx and ampicillin in vitro, these same mutants are tested in the CID and amp R screens. In addition to plate and more quantitative liquid lacZ assays, the mutants will be evaluated using a ura3 reporter gene. Ura3, which encodes orotidine-5′-phosphate decarboxylase and is required for uracil biosynthesis, is used routinely as a selectiable marker in yeast. Since large numbers of protein variants need to be screened for the evolution experiments, it will be important to move from a screen to a growth selection.
- Ura3 has the advantage that it can be used both for positive and negative selections-positive for growth in the absence of uracil and negative for conversion of 5-fluoroorotic acid (5-FOA) to 5-fluorouracil, a toxic byproduct. Cleavage of the cephem bond and disruption of ura3 transcription will be selected for based on growth in the presence of 5-FOA.
- the advantage to the 5-FOA selection is that the timing of addition of both the Dex-cephem-Mtx substrate and 5-FOA can be controlled.
- Mutants with higher activity will still show an enzyme-dependent signal (failure to hydrolyze X-gal or growth in the presence of 5-FOA/nitrocefin hydrolysis or resistance to ampicillin), but at some point these assays will not be able to detect the less active mutants.
- these experiments may bring surprising results. For example, it may be that detection correlates more strongly with k cat than with K M or k cat /K M . Assuming a dynamic range of >1000, we will proceed with the enzyme evolution experiments. Otherwise, we will focus on optimizing the sensitivity of the screen until we reach this level of sensitivity. The optimization experiments will continue along the same lines as the proof-of-principle experiments, varying the levels and timing of both protein expression and addition of the substrate and product, except they will be carried out with mutant cephases at the limit of detection.
- CIDs can be used to screen cDNA libraries based on biochemical function. This glycosidase example is used to determine the best method for expressing the cDNA clones and to optimize the screening process.
- Table III explains the components of each strain.
- Each strain was constructed from the parent yeast strain FY250 and also contains the pMW106 plasmid, which has the LacZ reporter gene that is turned on only in when the LexA DNA binding domain and the B42 activation are brought in tot he vicinity of each other.
- mDHFR is from murine
- eDHFR is from E. coli .
- the strain containing LexA-eDHFR with B42-rGH2 is a different strain and behaves differently from the strain containing LexA-rGR2 with B42-eDHFR.
- eDHFR E. coli Dihydrofolate Reductase
- rGR2 stereoid binding domain of rat Glucocorticoid Receptor (aa 524-795) with point mutations
- (rGR2) 3 trimer of rGR2
- mDHFR murineDihydrofolate Reductase
- gly6 6 amino acid linker conaining 6 glycines
- GSG 6 amino acid linker containing glycine-serine-glycine-glycine-serine-glycine.
- Table IV The results in Table IV are averages of two separate trials. Each strain was examined with small molecules and without small molecules. The absolute activity is given as the ⁇ -galactisidase activity with small molecule subtracted from the ⁇ -galactosidase activity without small molecule. The average ⁇ -galactosidse activity for a strain without small molecule (i.e. the negative control) was about 100 ⁇ -galactosidase units. V133Y is a positive control and shows ⁇ -galactosidase activity regardless of the presence of small molecule. The ⁇ -galactosidase activity of strain V494Y using varying concentrations of D8M is shown in FIG. 18 .
- Glycoconjugates are the most functionally and structurally diverse molecules in natures. (Varki, 1993) Moreover, it is now well established that carbohydrates and protein- and lipid-bound saccharides play essential roles in many important biological processes, including cell structure, protein targeting, and cell-cell interactions. (Varki, 1993) Accordingly, glycosidases with a broad array of substrate specificities are required to breakdown and modify polysaccharides, glycoproteins, and glycolipids.
- glycosidase activity There are many examples of well-characterized glycosidases identified in other organisms that are yet to be identified in S. cerevisiae .
- a-Amylase Sogaard, 1993; Vihinen, 1990; Qian, 1994 ; Wiegand, 1995; Fujimoto, 1998; Wilcox, 1984
- xylanase Wong, 1988; Biely, 1997) are endo-glycosidases that break down polysaccharides involved in energy storage and cell structure, respectively.
- Glycoproteins are synthesized by modification of a core glycoside.
- the GlcNAcb1®Asn and GlcNAcb1®4GlcNAc linkages in Asn-linked carbohydrates are cleaved by peptide-N 4 -(N-acetyl-b-glucosaminyl)asparagine amidase (PNGase F) and endo-b-N-acetylglucosaminidases (Endo H and Endo F1), respectively. (Tarentino, 1990; Tarentino, 1992; Robbins, 1984; Trimble, 1991) Since each of these enzymes are endo-glycosidases, the CID ligands should not interfere with the enzyme-catalyzed reaction. Likewise, by making a small library of carbohydrate linkers, we screen in an undirected fashion.
- the first step of both the chitinase control and the random oligosaccharide library is to introduce a S. cerevisiae cDNA library into the CID selection strain.
- a cDNA library reported by Fields and co-workers. (Martzen, 1999)
- each cDNA clone is expressed as a GST-fusion protein under control of a copper-inducible promoter on a shuttle vector with a leu2 marker.
- Transformation efficiencies in yeast are ca. 10 6 -10 7 using the lithium acetate method, so there is ample redundancy to screen all 6,000 ORFs in S. cerevisiae .
- Active clones can be identified by sequencing the plasmid.
- Chitinase hydrolyzes chitin, polymers of b-1,4-linked N-acetylglucosamine (GlcNAc) that play a structural role in the cell.
- GlcNAc N-acetylglucosamine
- the growing carbohydrate chain is linked to the solid support via the Glu portion of Mtx.
- the glycosidic linkages are formed essentially as reported by Kahne and co-workers using sulfoxide glycosyl donors. (Yan, 1994; Liang, 1996)
- the final carbohydrate is introduced as a Dex derivative, and the Mtx synthesis is completed prior to cleavage from the solid support.
- This synthesis allows the oligosaccharide linker to be varied and both the Dex and the Mtx ligand to be introduced before cleavage from solid support.
- the synthesis can be carried out in solution, (Kahne, 1989) or other methods for carbohydrate synthesis can be employed.
- lacZ plate assays are used to verify that the Dex-(GlcNAc) n -Mtx substrates are efficient dimerizers in the yeast three-hybrid assay.
- the results with Dex-cephem-Mtx support the feasibility of incorporating structurally diverse linkers into the CIDs. If the initial chitinase substrates, however, are not efficient dimerizers, the linkers between the CID ligands and the GlcNAc oligomer can be varied, or alternate dimerization assays can be tested. Since large numbers of cDNA clones need to be screened, the transcriptional read-out of the yeast three-hybrid assay may be changed from a screen to a growth selection.
- Ura3 which encodes orotidine-5′-phosphate decarboxylase and is required for uracil biosynthesis, replaced lacZ as the reporter gene.
- Ura3 has the advantage that it can be used both for positive and negative selections-positive for growth in the absence of uracil and negative for conversion of 5-fluoroorotic acid (5-FOA) to 5-fluorouracil, a toxic byproduct. Cleavage of the glycosidic bond and disruption of ura3 transcription is selected for based on growth in the presence of 5-FOA.
- the advantage to the 5-FOA selection is that the timing of addition of both the Dex-(GlcNAc) n -Mtx substrate and 5-FOA can be controlled.
- Several other reporter genes can be used.
- the Dex-(GlcNAc) n -Mtx substrate becomes unstable either because of its intrinsic half-life in water or because it is turned over by cellular glycosidases.
- the assay conditions can be modified so that the substrate is added late in the assay after the cells have grown to a high density, the substrate can be continuously replenished, or the pH of the media can be buffered. Turnover by cellular glycosidases can simply be seen as an assay in and of itself.
- random mutations can be introduced into the S. cerevisiae genome or the tagged knock-out strains of Winzeler et al. can be used. (Winzeler, 1999) Cells containing a disruptive mutation in the gene or genes cleaving the Dex-(GlcNAc) n -Mtx substrate can be selected for by growth in the absence of uracil.
- the final step is to use the Dex-(GlcNAc) n -Mtx substrate to pull out chitinase from a S. cerevisiae cDNA library.
- a 5-FOA growth selection is used to screen the Fields cDNA library.
- Dex-(GlcNAc) n -Mtx induces ura3 transcription, and 5-FOA is converted to the toxic byproduct 5-fluorouracil.
- only cells containing active chitinase, or another enzyme that can cleave the substrate survive.
- the cDNA clone is readily identified by isolating the plasmid, sequencing the N-terminus of the clone, and comparing this sequence to that of the S. cerevisiae genome.
- the advantage of using a known enzyme is that the enzyme can be tested independently or used to spike the cDNA library.
- the enzyme can be purified, and the Dex-(GlcNAc) n -Mtx substrate can be tested in vitro.
- the next step is to determine the activity of the >3000 ORFs in S. cerevisiae with unknown function.
- the screen is run exactly as with the chitinase control except using Dex-oligosaccharide-Mtx substrates with different glycosidic linkages.
- the glycosidic linkages is based on the types of carbohydrates and glycoconjugates naturally occuring in yeast.
- amylase (Sogaard, 1993; Vihinen, 1990; Qian, 1994; Wiegand, 1995; Fujimoto, 1998; Wilcox, 1984) xylanase, (Wong, 1988; Biely, 1997; Georis, 1999) and endo-N-acetylglucosamine hydrolysis activity, (Tarentino, 1990; Tarentino, 1992; Robbins, 1984; Trimble, 1991) can be targeted specifically.
- Dex-Mtx CIDs with different oligosaccharide linkers are prepared using the same strategy as for the chitinase substrate (above).
- the sulfoxide glycosyl donor method for carbohydrate synthesis allows a variety of sugar monomers to be introduced. (Kahne, 1989) Moreover, both the regio- and stereo-chemistry can be controlled. (Yan, 1994; Liang, 1996).
- the 5-FOA growth selection is used to identify enzymes that cleave the various glycosidic linkages. Each glycoside subsrate is tested individually. Mixtures of substrates cannot be tested because the uncleaved substrates would continue to activate ura3 transcription. If the screen does not pick up any enzymes, known glycosidases from other organisms may be used as controls both for the growth selections and to test the Dex-Mtx substrates in vitro.
- the foregoing permits the characterization of in vitro activity and biological function of glycosidases identified using the CID screen.
- cDNA libraries from other organisms can be screened.
- the Dex-Mtx substrates can be used to evolve glycosidases with unique specificities.
- the cDNA screen can be extended to other classes of enzymes, such as proteases.
- the Diels-Alder reaction is one of the key carbon-carbon bond forming reactions in synthetic organic chemistry ( FIG. 7B ).
- Diels-Alderases Surprisingly, no natural Diels-Alderases are known, although catalytic antibodies have been generated for this reaction.
- B. subtilis chorismate mutase is evolved into a “Diels-Alderase” that can catalyze the cycloaddition of 1-carbamyl-1, 3-butadiene and 2-propanoic acid ( FIG. 7B ).
- Chorismate mutase catalyzes the Claisen rearrangement of chorismate to prephenate ( FIG. 7A ).
- the Claisen rearrangement is a pericyclic reaction with a six-membered transition state (ts). This similarity—and inspection of the active site—suggests that the chorismate mutase active site can accommodate a Diels-Alder transition state.
- the structures of the B. subtilis and E. coli enzymes and of an antibody that catalyzes this reaction in complexes with a ts analog have been determined to high resolution.
- the CM structural data allows design the diene and dienophile (1) to utilize the electrostatic environment in the CM active site and (2) to incorporate H1 and H2 without disrupting substrate binding. It may be necessary, however, to incorporate additional functionality to improve substrate binding or to modulate the eletrophilicity of the dienophile to prevent reaction with cellular components.
Abstract
Description
H1-X-B-Y-H2
wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety. This invention also provides a method of screening proteins for the ability to catalyze bond cleavage, comprising the steps of:
-
- a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;
- b) providing the compound of the invention which dimerizes the pair of fusion proteins, said compound comprising two portions coupled by a bond that is cleavable by the protein to be screened; and
- c) screening for the cellular readout, wherein a change the cellular readout indicates catalysis of bond cleavage by the protein to be screened. Finally, the invention also provides a method of screening proteins for the ability to catalyze bond formation, comprising the steps of:
- a) providing a cell that expresses a pair of fusion proteins which upon dimerization activate a cellular readout:
- b) providing a first compound and a second compound, each being capable of binding to one of the pair of fusion proteins, said first and second compound comprising a portion through which the first and second compounds are coupled to form the inventive compound by the action of the bond forming protein to be screened; and
- c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond formation by the protein to be screened.
H1-X-B-Y-H2
wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different; wherein each of X and Y may be present or absent and if present, each may be the same or different spacer moiety; and wherein B is an enzyme cleavable moiety.
H1-X-B′
with a second compound having the formula:
H2-Y-B″
wherein B′ and B″ are moieties that react to form B in the presence of an enzyme.
H1-X-B′
wherein H1 is capable of binding to a receptor;
wherein X is a spacer moiety which may be present or absent; and
wherein B′ is a moiety capable of binding to an enzyme.
H2-Y-B″
wherein H2 is capable of binding to a receptor; wherein Y is a spacer moiety which may be present or absent; wherein B″ is a moiety that reacts with B′ in the presence of the enzyme.
-
- a) providing a cell that expresses a pair of fusion proteins which upon dimerization change a cellular readout;
- b) providing a compound which dimerizes the pair of fusion proteins, said compound comprising two portions coupled by a bond that is cleavable by the protein to be screened; and
- c) screening for the cellular readout, wherein a change the cellular readout indicates catalysis of bond cleavage by the protein to be screened.
-
- a) providing a cell that expresses a pair of fusion proteins which upon dimerization activate a cellular readout:
- b) providing a first compound and a second compound, each being capable of binding to one of the pair of fusion proteins, said first and second compound comprising a portion through which the first and second compounds are coupled by the action of the bond forming protein to be screened; and
- c) screening for the cellular readout, wherein a change in the cellular readout indicates catalysis of bond formation by the protein to be screened.
-
- screening for activity of the enzyme by the method disclosed herein, and obtaining cells which express an active enzyme, and
- contacting the cells with the drug to be screened, wherein a change in the transcription of the reporter gene within the cell after contact with the drug indicates inhibition of the enzyme by the drug.
-
- evolving mutants of the natural coenzyme; and
- screening the mutants of the natural coenzyme in the presence of a cofactor different from the cofactor of the natural enzyme, using either of the screening methods provided by this invention.
H1-Y-H2
wherein H1 is methorexate or an analog thereof;
wherein H2 is capable of binding to a receptor, and
wherein Y is a moiety providing a covalent linkage between H1 and H2, which may be present or absent, and when absent, H1 is covalently linked to H2. H2 may be Dex or an analog thereof. When H1 is Mtx, then H2 may be Dex or an analog thereof.
-
- (a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety or an analog of methotrexate to form a screening molecule;
- (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the known target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
- (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;
- (d) selecting which cell expresses the reporter gene; and
- (e) identifying the small molecule that binds the known target.
-
- (a) providing a screening molecule comprising a methotrexate moiety or an analog of methotrexate covalently bonded to a ligand which has a specificity for an unknown protein target;
- (b) introducing the screening molecule into a cell which expresses a first fusion protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the unknown protein target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
- (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;
- (d) selecting which cell expresses the reporter gene; and
- (e) identifying the unknown protein target.
and antibiotics, such as Coumermycin (which can be used to induce protein dimerization according to Perlmutter et al., Nature 383, 178 (1996)).
-
- 1) Glycosidase bond, which may be cleaved by a Glycosidase enzyme and formed by a Glycosyltrasferase enzyme
-
- 2) Phosphodiester bond.
-
- 3) Amide bond, which may be cleaved by protease and formed by peptidase or transpeptidase. An example of such a bond is a cephem bond shown in
FIGS. 4 and 12 . - 4) Ester bond.
- 3) Amide bond, which may be cleaved by protease and formed by peptidase or transpeptidase. An example of such a bond is a cephem bond shown in
-
- 5) Aldol product bond, which is cleaved by a retro-aldolase and formed by Aldolase.
- 1.1 CH—OH, 1.2 aldehyde or oxo, 1.3 CH—CH, 1.4 CH—NH2, 1.5 CH—NH, 1.6 NADH OR NADPH, 1.7 other N-containing, 1.8 sulfur, 1.9 heme, 1.10 diphenols and related, 1.11 peroxidases, 1.12 hydrogen, 1.13 single donors+O2, 1.14 paired donors+O2, 1.15 superoxide radical, 1.16 oxidizing metal ions, 1.17 CH2, 1.18 reduced ferredoxin, and 1.19 reduced flavodoxin.
- 2.1 one carbon, 2.2 aldehydes or ketones, 2.3 acyl, 2.4 glycosyl, 2.5 alkyl or aryl, 2.6 N-containing, 2.7 P-containing, 2.8 S-containing, and 2.9 Se-containing.
- 3.1 ester, 3.2 glycosidic, 3.3 ether, 3.4 peptide, 3.5 C—N (non-peptide), 3.6 acid anhydride, 3.7 C—C, 3.8 C-halide, 3.9 P—N, 3.10 S—N, 3.11 C—P, and 3.12 S—S.
- 4.1 C—C, 4.2 C—O, 4.3 C—N, 4.4 C—S, 4.5 C-halide, and 4.6 P—O.
- 5.1 racemases and epimerases, 5.2 cis-trans isomerases, 5.3 intra-oxidoreductases, 5.4 intra-transferases (mutases), and 5.5 intramolecular lyases.
- 6.1 C—O, 6.2 C—S, 6.3 C—N, 6.4 C—C, and 6.5 P-ester.
TABLE I |
Effect of DEX-Mtx on Dimerization of Different LexA-and |
B42-Protein Fusions |
Straina | LexA Chimera | B42 Chimera | Dex- |
1 | LexA-eDHFRc | B42-Gly6 d-rGR2e | Yes | |
2 | LexA-eDHFR | B42- | No | |
3 | LexA-eDHFR | B42-(rGR2)3 | |
|
4 | LexA-mDHFRf | B42-Gly6- | No | |
5 | LexA-mDHFR | B42- | No | |
6 | LexA-mDHFR | B42-(rGR2)3 | No | |
7 | LexA-rGR2 | B42- | No | |
8 | LexA-rGR2 | B42- | No | |
9 | LexA-(rGR2)3 | B42- | No | |
10 | LexA-(rGR2)3 | B42-mDHFR | No | |
a S. Cerevisiae strain FY250 containing pMW106 (the lacZ reporter plasmid), pMW103 (encoding the LexA chimera), and pMW012 (encoding the B42 chimera). | ||||
bDex-Mtx-dependent dimerization was determined using standard assays for lacZ transcription. See the text for details. | ||||
cthe E. coli DHFR. | ||||
dIn some contructs a 6 Glycine linker was added between B42 and the rGR. | ||||
eA mutant form of the hormone-binding domain of the glucocorticoid receptor (residues 524-795, Phe620 -Ser, Cys656 -Gly) with increased affinity for Dex was used in these studies. | ||||
fthe murine DHFR. |
TABLE II |
Wild-type and mutant enzymes are shown with their kinetic |
rate constants with the chromogenic cephalosporin nitrocefin, |
as well as the percentage of wild-type kcat/Km as calculated in |
that experiment. |
kcat/Km |
Enzyme | Km (μM) | kcat (s−1) | (M−1 s−1) | % WT |
E. cloacae P99 wt | 25 ± 1 | 780 ± 30 | 3.1 × 107 | 100 |
E. cloacae Q908R wt | 23 ± 1 | 780 ± 30 | 3.4 × 107 | 100 |
K12 AmpC wt | 500 ± 100 | 490 ± 90 | 1.0 × 106 | 100 |
P99 286-290 TSFGN | 19 ± 0.5 | 261 ± 7 | 1.37 × 107 | 96 |
P99 286-290 LTSNR | 43 ± 2 | 330 ± 11 | 7.7 × 106 | 54 |
P99 286-290 NNAGY | 31 ± 11 | 53 ± 10 | 1.7 × 106 | 12 |
K12 Y150S | 108 ± 21 | 2.11 ± 0.12 | 1.9 × 104 | ~1 |
K12 Y150E | 356 ± 34 | 0.51 ± 0.03 | 1.4 × 103 | ~0.1 |
Q908R S64C | >1000 | >18 | 1.76 × 104 | 0.05 |
TABLE III | |||
Strain | LexA | B42 | |
V375Y | eDHFR | gly6rGR2 | |
V493Y | eDHFR | rGR2 | |
V496Y | mDHFR | gly6rGR2 | |
V495Y | mDHFR | rGR2 | |
V505Y | rGR2 | eDHFR | |
V507Y | rGR2 | mDHFR | |
V501Y | (GSG)2eDHFR | (GSG)rGR2 | |
V504Y | (GSG)2mDHFR | (GSG)rGR2 | |
V494Y | eDHFR | (GSG)rGR2 | |
V497Y | mDHFR | (GSG)rGR2 | |
V510Y | (GSG)2rGR2 | (GSG)2eDHFR | |
V512Y | (GSG)2rGR2 | (GSG)2mDHFR | |
V498Y | (GSG)2eDHFR | rGR2 | |
V502Y | (GSG)2mDHFR | rGR2 | |
V499Y | (GSG)2eDHFR | gly6rGR2 | |
V503Y | (GSG)2mDHFR | gly6rGR2 | |
V509Y | rGR2 | (GSG)2eDHFR | |
V511Y | rGR2 | (GSG)2mDHFR | |
V506Y | (GSG)2rGR2 | eDHFR | |
V508Y | (GSG)2rGR2 | mDHFR | |
V513Y | eDHFR | (rGR2)3 | |
V514Y | mDHFR | (rGR2)3 | |
V517Y | (rGR2)3 | eDHFR | |
V518Y | (rGR2)3 | mDHFR | |
V515Y | (GSG)2eDHFR | (rGF2)3 | |
V516Y | (GSG)2mDHFR | (rGR2)3 | |
V134Y | Sec16p | Sec6p | positive control |
V133Y | Sec13 | Sec6p | positive control |
V381Y | blank | blank | negative control |
V379Y | eDHFR | blank | negative control |
V560Y | blank | (GSG)2rGR2 | negative control |
Identification of stains used. (Key: eDHFR = E. coli Dihydrofolate Reductase; rGR2 = stereoid binding domain of rat Glucocorticoid Receptor (aa 524-795) with point mutations; (rGR2) 3 = trimer of rGR2; mDHFR = murineDihydrofolate Reductase; gly6 = 6 amino |
β-Galactosidase Activity Assay Results
TABLE IV |
β-galactosidase Activity Assays |
B- |
1 |
1 |
1 uM | |||
Strains | DM1 | D8M | D10M | Controls | B-gal activity |
V375Y | 4978 | 5210 | 9993 | V133Y | 1912 | (Positive |
V493V | 5753 | 5555 | 5812 | Control) | ||
V496Y | −30 | −27 | 740 | No small | 96.9374475 | (Negative |
V495Y | 15 | 38 | 513 | molecules | Control) | |
V505Y | 557 | 2532 | 1160 | |||
V507Y | −7 | −6 | −14 | |||
V501Y | 4662 | 6660 | 2286 | |||
|
12 | 30 | 556 | |||
V494Y | 9976 | 10568 | 9398 | |||
V497Y | −8 | 24 | 308 | |||
V510Y | 601 | 3163 | 2314 | |||
V512Y | −1 | −4 | 6 | |||
V498Y | 4735 | 5442 | 2926 | |||
V502V | 21 | 30 | 497 | |||
V499Y | 4368 | 7012 | 4013 | |||
V503Y | −5 | 45 | 1132 | |||
V509Y | 307 | 2734 | 2028 | |||
V511Y | −113 | −129 | −60 | |||
V506Y | 519 | 3867 | 2561 | |||
|
0 | −5 | 5 | |||
- Albrecht, H.; et al. J. Med. Chem. (1990), 33, 77-86.
- Amara, J. et al, PNAS. USA (1997), 94, 10618-10623.
- Austin D J, et al., Chem Biol. (1994 November), 1(3): 131-6. Review.
- Baca, M.; Scanlan, T.; Stephenson, R.; Wells, J. Proc. Natl Acad. USA (1997), 94, 10063-10068.
- Banoub, J. Chem. Rev. (1992) 92, 1167-1195.
- Baum E Z, Bebernitz G A, Gluzman Y., Proc Natl Acad Sci USA. (1990 December), 87(24):10023-7.
- Belshaw P J, et al., Chem. Biol., (1996(a)) September, 3(9); 731-8.
- Belshaw P J, et al., Proc Natl Acad Sci USA (1996(b)) May 14, 93(10): 4604-7.
- Biely, P.; Vrsanska, M.; Tenkanen, M.; Kluepfel, D. J. Biotechnol. (1997) 57, 151-166.
- Filman, D.; Matthews, D.; Kraut, J. J. Biol. Chem. (1982), 257, 13663-13672.
- Boons, G. Tetrahedron (1996) 52, 1095-1121.
- Braisted, A.; Schultz, P. J. Am. Chem. Soc. (1990), 112, 7430-7431.
- Braselmann, S.; Graninger, P.; Busslinger, M., PNAS, USA (1993) 90, 1657-1661.
- Carruthers, W. Cycloaddition Reactions in Organic Synthesis; Pergamon Press: Oxford, (1990); Vol. 8.
- Chakraborti, P.; Garabedian, M.; Yamamoto, K.; S S Simons. J. J. Biol. Chem. (1991), 266. 22075-22078.
- Chook, Y.; Gray, J.; Ke, H.; Lipscomb, W. J. Mol. Biol. (1994), 240, 476-500.
- Choi J. et al., Science, Jul. 12, 1996; 273(5272): 239-42.
- Clackson, T. et al., (1998) PNAS, USA 95, 10437-10442.
- Coleman, R.; Danishefsky, S. 28 (1989), 157-161.
- Correat, J. U.; Elango, N.; Polacheck, I.; Cabib, E. J. Biol. Chem. (1982) 257, 1392-1397.
- Crabtree, G.; Schreiber, S. Trends Biochem. Sci. (1996), 21, 418-422.
- Crameri, A.; Raillard, S.-A.; Bermudez, E.; Stemmer, W. Nature (1998), 391, 288-91.
- Danishefsky, S. J.; McClure, K. F.; Randolph, J. T.; Ruggeri, R. B. Science (1993) 260, 1307-1309.
- DeGrado, W.; Nilsson, B. Curr. Opin. Struc. Biol. (1997), 7, 455-456.
- Diver, S T, Journal of the American Chemical Society, (1997 Jun. 4), V119 N22; 5106-5109.
- Duchene, A.; et al. Synlett (1994), 524-526.
- Durckheimer, W.; Adam, F.; Fischer, G.; Kirrstetter, R. Adv. Drug Res. (1988), 17, 61-234.
- Eisenbeis, S.; et al. Proc. Natl. Acad. Sci. USA (1985), 82, 1084-1089.
- Fields, S.; Song, O. Nature (1989), 340, 245-246.
- Fujimoto, Z.; et al. J. Mol. Biol. (1998) 277, 393-407.
- Galleni, M.; Frere, J. Biochem. J. (1988(a)), 255, 119-122.
- Galleni, M; Amicosante, G.; Frere, J. Biochem. J. (1988(b)), 255, 123-129.
- Galleni, M.; et al. Biochem J. (1988(c)), 250, 753-760.
- Ghuysen, J. Annu. Rev. Microbiol. (1991) 45, 37-67.
- Gossen, M.; Bujard, H. PNAS, USA (1992) 89, 5547-5551.
- Gossen, M.; Freundlieb, S.; Bender, G.; Muller, G.; Hiller, W.; Bujard, H., Science (1995) 268, 1766-1769.
- Gouverneur, V.; et al. Science (1993), 262, 204-208.
- Govindan, M.; Manz, B. Eur. J. Biochem. (1980), 108, 47-53.
- Gray, J.; Golinelli-Pimpaneau, B.; Knowles, J. Biochemistry (1991), 29, 376-383.
- Gray, J.; Eren, D.; Knowles, J. Biochemistry (1990), 29, 8872-8878.
- Gyuris, J.; Golemis, E.; Chertkov, H.; Brent, R. Cell (1993), 75, 791-803.
- Haynes, M.; Sutra, E.; Hilvert, D.; Wilson, I. Science (1994), 263, 646-652.
- Hawkins C J, Wang S L, Hay B A. Proc. Natl. Acad. Sci. USA (Mar. 16, 1999);96(6):2885-90.
- Hermes, J.; Blacklow, S.; Knowles, J. Proc. Natl. Acad. Sci. USA (1990), 87, 696-700.
- Hilvert, D.; Kaiser, E. J. Am. Chem. Soc. (1985), 107, 5805-5806.
- Hilvert, D. Curr. Opin. Struct. Biol. (1994), 4, 612-617.
- Hilvert, D.; Hill, K.; Nared, K.; Auditor, M.-T. J. Am. Chem. Soc. (1989(c)), 111, 9261-9262.
- Ho S N, et al., Nature, (Aug. 29, 1996); 382(6594): 822-6.
- Holsinger L J, et al., Proc Natl Acad Sci USA (Oct. 10, 1995), 92(21): 9810-4.
- Hu, J.; O'Shea, E.; Kim, P.; Sauer, R. Science (1990), 250, 1400-1403.
- Hu, J. Structure (1995), 3, 431-433.
- Huang, T.; Barclay, B.; Kalman, T.; vonBorstel, R.; Hastings, P. Gene (1992), 121, 167-171.
- J. Hudson; Fields, S.; et al. Genome Res. (1997) 7, 1169-1173.
- Hung, D T, Chemistry & Biology, (1996 August), V3 N8: 623-639.
- Imperiali, B.; Roy, R. J. Am. Chem. Soc. (1994), 116, 12083-12084.
- Jacobsen, J.; et al. Science (1992), 256, 365-367.
- Johnson K.; Allemann, R.; Widmer, H.; Benner, S. Nature (1993), 365, 530-532.
- Johnsson, N.; Varshavsky, A. Proc. Natl. Acad. Sci. USA (1994), 91, 10340-10344.
- Kahne, D.; Walker, S.; Cheng, Y.; Engen, D. V. J. Am. Chem. Soc (1989) 111, 6881-6882.
- Kaiser, E.; Lawrence, D. Science (1984), 226, 505-511.
- Kamada S, Kusano H, Fujita H, Ohtsu M, Koya R C, Kuzumaki N, Tsujimoto Y. Proc Natl Acad Sci USA. (Jul. 21, 1998); 95(15):8532-7.
- Karimova, G.; Pidoux, J.; Ullmann, A.; Ladant, D. Proc. Natl. Acad. Sci. USA (1998),95, 5752-5756.
- Kast, P.; Asif-Ullah, M.; Jiang, N.; Hilvert, D. Proc. Natl. Acad. Sci. USA (1996), 93, 5043-5048.
- Kelly, J.; et al. Science (1986) 231, 1429-1437.
- Knowles, J. Science (1987), 236, 1252-1258.
- Koltermann, A.; et al. Proc. Natl. Acad. Sci. USA (1998), 95, 1421-1426.
- Klemm, J D, Annu Rev Immunol, (1998), 16:569-92.
- Knox, J.; Moews, P.; Frere, J. Chemistry & Biology (1996) 3, 937-947.
- Kralovec, J.; Spencer, G.; Blair, A.; Mammen, M.; Singh, M.; Ghose, T. J. Med. Chem. (1989), 32, 2426-2431.
- Kuranda, M. J.; Robbins, P. W. Proc. Natl. Acad. Sci. USA (1987) 84, 2585-2589.
- Kuranda, M. J.; Robbins, P. W. J. Biol. Chem. (1991) 266, 19758-19767.
- Lee, A.; Karplus, P.; Ganem, B.; Clardy, J. J. Am. Chem. Soc. (1995), 117, 3627-3628.
- Leung, D.; Chen, E.; Goeddel, D. Technique (1989), 1, 11-15.
- Liang, R.; Kahne, D.; et al. Science (1996) 274, 1520-1522.
- Licitra, E.; Liu, J. Proc. Natl. Acad. Sci. USA (1996), 93, 12817-12821.
- Lin, H, Abida, W., Sauer, R., Cornish, V., J. Am. Chem. Soc. (2000), 122, 4247-4248.
- Lobkovsky, E.; et al. Proc. Natl. Acad. Sci. USA (1993), 90, 11257-11261.
- Manz, B.; Heubner, A.; Kohler, I.; Grill, H.-J.; Pollow, K. Eur. J. Biochem. (1983), 131, 333-338.
- Martzen, M. R.; McCraith, S. M.; Spinelli, S. L.; Torres, F. M.; Fields, S.; Grayhack, E. J.; Phizicky, E. M. Science (1999) 286, 1153-1155.
- Meyer, D.; et al. Bioconjugate Chem. (1995), 6, 440-446.
- Monnaie, D.; Virden, R.; Frere, J. FEBS (1992), 306, 108-112.
- No, D.; Yao, T.; Evans, R. PNAS, USA (1996) 93, 3346-3351.
- Oppolzer, W. In Comp. Org. Syn.; B. Trost and I. Fleming, Eds.; Pergamon Press: New York, (1991); Vol. 5; pp 315-399.
- Overman, L; Taylor, G.; Petty, C.; Jessup, P. J. Org. Chem. (1978), 43, 2164-2167.
- Page, M., The chemistry of the b-lactams, Ed.; Chapman & Hall: Glasgo, (1992).
- Pedersen, H.; et al. Proc. Acad. Sci. USA (1998), 95, 10523-10528.
- Picard, D.; Yamamoto, K. EMBO J. (1987), 6, 3333-3338.
- Pluckthun, A.; Knowles, J. J. Biol. Chem. (1987), 262, 3951-3957.
- Posner, B.; Smiley, J.; Lee, I.; Benkovic, S. Trends Biochem. Sci. (1994), 19, 145-150.
- Pruschy, M.; Spencer, D.; Kapoor, T.; Miyake, H.; Crabtree, G.; Schreiber, S. Chem. Biol. (1994), 1, 163-172.
- Qian, M.; Haser, R.; Buisson, G.; Duee, E.; Payan. F. Biochemistry (1994) 33, 6284-94.
- Reidhaar-Olson, J.; et al. Methods Enz. (1991), 208, 564-586.
- Robbins, P.; Trimble, R.; Wirth, D.; Hering, C.; Maley, F.; Maley, G.; Das, R.; Gibson, B.; Royal, N.; Biemann, K. J. Biol. Chem. (1984) 259, 7577-7583.
- Rossi, R.; Charlton, C.; Blau, H. Proc. Natl. Acad. Sci. (1997), 94, 8405-8410.
- Rosen, M.; Schreiber, S., Angew Chem. Int. Ed. Engl. (1992) 31, 384-400.
- Sasso, S.; Gilli, R.; Sari, J.; Rimet, O.; Briand, C. Biochim. Biophys. Acta (1994), 1207, 74-79.
- Schmidt, R. Angew. Chem. Int. Ed. Engl. (1986) 25, 212-235.
- Schreiber, S L, Bioorg Med Chem (1998 August); 6(8): 1127-52.
- Schultz, P. Ang. Chem. Int. Ed. Eng. (1989(a)), 28, 1283-1444.
- Schultz, P.; Lerner, R. Science (1995), 269(b), 1835-1842.
- Seeberger, P. H.; Danishefsky, S. J. Acc. Chem. Res (1998) 31, 685-695.
- Shokat, K.; Leumann, C.; Sugasawara, R.; Schultz, P. Science (1989), 338, 269-272.
- Smith T A, Kohorn B D. Proc Natl Acad Sci USA. (Jun. 15 1991); 88(12): 5159-62.
- Sogaard, M.; Kadziola, A.; Haser, R.; Svensson, B. J. Biol. Chem. (1993) 268, 22480-22484.
- Spencer D M, et al., Curr Biol. (Jul. 1, 1996), 6(7): 839-47.
- Spencer D M, et al., Proc Natl Acad Sci USA (1995 Oct. 10), 92(21): 9805-9.
- Spencer, D.; Wandless, T.; Schreiber, S.; Crabtree, G. Science (1993), 262, 1019-1024.
- Stemmer, W. Proc. Natl. Acad. Sci. USA (1994(a)), 91, 10747-10751.
- Stemmer, W. Nature (1994(b)), 370, 389-391.
- Stockwell, B R, Chem. Biol., (1998(a) July 5)(7): 385-95.
- Stockwell, B R, Curr. Biol., (1998(b) June 18); 8(13): 761-70.
- Suckling, C.; et al. Biorg. Med. Chem. Lett. (1992), 2, 49-53.
- Tarentino, A.; Quinones, G.; Trumble, A.; Changchien, L.; Duceman, B.; Maley, F. J. Biol. Chem. (1990) 265, 6961-6966.
- Tarentino, A.; T H Plummer, J.; et al. J. Biol. Chem. (1992) 267, 3868-3872.
- Toshima, K.; Tatsuta, K. Chem. Rev. (1993) 93, 1503-1531.
- Trimble, R.; Tarentino, A. J. Biol. Chem. (1991) 266, 1646-1651.
- Varki, A. Glycobiology (1993) 3, 97-130.
- Vihinen, M.; Mantsala, P.; et al. J. Biochem. (1990) 107, 267-272.
- Vrudhula, V.; Svensson, H.; Senter, P. J. Med. Chem. (1995), 38, 1380-1385.
- Wagner, J.; Lerner, R.; Barbas, C. Science (1995), 270, 1797-1800.
- Wagner, R.; Rhoades, T.; Or, Y.; Lane, B.; Hsieh, G.; Mollison, K.; Luly, J. J. Med. Chem. (1998), 41, 1764-1776.
- Wang, Y.; B W O'Malley, J.; Tsai, S.; O'Malley, B.PNAS, USA (1994) 91, 8180-8184.
- Wells, J.; Vasser, M.; Powers, D. Gene (1985), 34, 315-323.
- Wharton, R.; Patashne, M. Nature (1985), 316, 601-605.
- Wiegand, G.; Epp, O.; Huber, R. J. Mol. Biol. (1995) 247, 99-110.
- Wilcox, E.; Whitaker, J. Biochemistry (1984) 23, 1783-1791.
- Wilks, H.; et al. Science (1988), 242, 1541-1544.
- Wong, K.; Tan, L.; Saddler, J. Microbiol. Rev. (1988) 52, 305-317.
- Yan, L.; Taylor, C. M.; R. Goodnow, J.; Kahne, D. J. Amer. Chem. Soc. (1994) 116, 6953-6954.
- Yang J., Curr Biol (1998 Jan. 1), 8(1): 11-8.
- Ye, X.; Wong, C. J. Org. Chem. (2000) 65, 2410-2431.
- Zhang, J.; Dawes, G.; Stemmer, W. Proc. Natl. Acad. Sci. USA (1997), 94, 4504-4509.
- Zhang, Z.; Ollmann, I. R. J. Amer. Chem. Soc. (1999) 121, 134-153.
- Zlokarnik, G.; et al. Science (1998) 279, 84-88
- Zoller, M.; Smith, M. Methods Enz. (1983), 200, 468-500.
Claims (28)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/705,644 US7419780B2 (en) | 2000-01-24 | 2003-11-10 | Methods and assays for screening protein targets |
US12/221,180 US20100261167A1 (en) | 2000-01-24 | 2008-07-30 | In vivo screen using chemical inducers of dimerization |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49032000A | 2000-01-24 | 2000-01-24 | |
US09/768,479 US20020004202A1 (en) | 2000-01-24 | 2001-01-24 | In vivo screen using chemical inducers of dimerization |
US10/705,644 US7419780B2 (en) | 2000-01-24 | 2003-11-10 | Methods and assays for screening protein targets |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/768,479 Division US20020004202A1 (en) | 2000-01-24 | 2001-01-24 | In vivo screen using chemical inducers of dimerization |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/221,180 Division US20100261167A1 (en) | 2000-01-24 | 2008-07-30 | In vivo screen using chemical inducers of dimerization |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040106154A1 US20040106154A1 (en) | 2004-06-03 |
US7419780B2 true US7419780B2 (en) | 2008-09-02 |
Family
ID=23947547
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/768,479 Abandoned US20020004202A1 (en) | 2000-01-24 | 2001-01-24 | In vivo screen using chemical inducers of dimerization |
US10/705,644 Expired - Fee Related US7419780B2 (en) | 2000-01-24 | 2003-11-10 | Methods and assays for screening protein targets |
US12/221,180 Abandoned US20100261167A1 (en) | 2000-01-24 | 2008-07-30 | In vivo screen using chemical inducers of dimerization |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/768,479 Abandoned US20020004202A1 (en) | 2000-01-24 | 2001-01-24 | In vivo screen using chemical inducers of dimerization |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/221,180 Abandoned US20100261167A1 (en) | 2000-01-24 | 2008-07-30 | In vivo screen using chemical inducers of dimerization |
Country Status (5)
Country | Link |
---|---|
US (3) | US20020004202A1 (en) |
EP (1) | EP1254179A4 (en) |
AU (1) | AU2001229741A1 (en) |
CA (1) | CA2398010A1 (en) |
WO (1) | WO2001053355A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162858A1 (en) * | 2007-09-18 | 2009-06-25 | Cornish Virginia W | Orthogonal chemical inducer of dimerization |
US20100261167A1 (en) * | 2000-01-24 | 2010-10-14 | The Trustrees Of Columbia University In The City Of New York | In vivo screen using chemical inducers of dimerization |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828099B2 (en) * | 1998-02-02 | 2004-12-07 | Odyssey Thera Inc. | Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase |
US20020168737A1 (en) * | 2001-01-24 | 2002-11-14 | Cornish Virginia W. | Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization |
US20030165873A1 (en) * | 2001-03-02 | 2003-09-04 | Come Jon H. | Three hybrid assay system |
US20030138785A1 (en) * | 2001-12-21 | 2003-07-24 | Stephan Kopytek | In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID") |
US7083918B2 (en) | 2002-04-24 | 2006-08-01 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
WO2004078594A2 (en) | 2003-03-03 | 2004-09-16 | The Trustees Of Columbia University In The City Of New York | Ligand/binding partner bio-labeling systems |
US8603751B2 (en) | 2006-03-02 | 2013-12-10 | The Uab Research Foundation | Mycobacterial disease detection, treatment, and drug discovery |
WO2008005529A2 (en) * | 2006-07-07 | 2008-01-10 | The Trustees Columbia University In The City Of New York | Cell-mediated directed evolution |
WO2010077470A2 (en) * | 2008-11-19 | 2010-07-08 | University Of Washington | Enzyme catalysts for diels-alder reactions |
US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
US10634668B2 (en) * | 2012-09-13 | 2020-04-28 | Takara Bio Usa, Inc. | Modifiable chemical inducers of proximity and methods of using the same |
BR112015013715A2 (en) * | 2012-12-12 | 2017-09-26 | Promega Corp | system, method for capturing cell target, cell lysate and capture ligand. |
US10168323B2 (en) | 2013-03-15 | 2019-01-01 | Promega Corporation | Compositions and methods for capture of cellular targets of bioactive agents |
EP3365442B8 (en) * | 2015-10-23 | 2022-06-08 | Fred Hutchinson Cancer Center | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events |
WO2017156238A1 (en) * | 2016-03-11 | 2017-09-14 | President And Fellows Of Harvard College | Protein stability-based small molecule biosensors and methods |
WO2020257794A2 (en) * | 2019-06-21 | 2020-12-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for metabolic engineering |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
US5314817A (en) | 1988-11-18 | 1994-05-24 | The Regents Of The University Of California | Catalytic and reactive polypeptides and methods for their preparation and use |
US5468614A (en) | 1990-01-24 | 1995-11-21 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
WO1996030540A2 (en) | 1995-03-20 | 1996-10-03 | The Regents Of The University Of California | Substrates for beta-lactamase and uses thereof |
EP0742015A1 (en) | 1990-11-06 | 1996-11-13 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
WO1997031113A1 (en) | 1996-02-23 | 1997-08-28 | Ariad Pharmaceuticals, Inc. | Cell-based assay |
WO1998013353A1 (en) | 1996-09-26 | 1998-04-02 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and use for cellular assays in drug discovery |
US5736343A (en) | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
WO1999010508A1 (en) | 1997-08-27 | 1999-03-04 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
WO1999010510A2 (en) | 1997-08-26 | 1999-03-04 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
US5928868A (en) | 1996-04-26 | 1999-07-27 | Massachusetts Institute Of Technology | Three hybrid screening assay |
US6030785A (en) | 1997-03-05 | 2000-02-29 | University Of Washington | Screening methods to identify agents that selectively inhibit hepatitis C virus replication |
WO2002059272A2 (en) | 2001-01-24 | 2002-08-01 | The Trustees Of Columbia University In The City Of New York | Covalent chemical inducers of protein dimerization and their uses in high throughput binding screens |
WO2003060073A2 (en) | 2001-12-21 | 2003-07-24 | The Trustees Of Columbia University In The City Of New York | An in vivo protein screen based on enzyme-assisted chemically induced dimerization ('cid') |
US20030203471A1 (en) | 2002-04-24 | 2003-10-30 | Althoff Eric A. | Bacterial small-molecule three-hybrid system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020004202A1 (en) * | 2000-01-24 | 2002-01-10 | Cornish Virginia W. | In vivo screen using chemical inducers of dimerization |
-
2001
- 2001-01-24 US US09/768,479 patent/US20020004202A1/en not_active Abandoned
- 2001-01-24 WO PCT/US2001/002285 patent/WO2001053355A1/en active Application Filing
- 2001-01-24 AU AU2001229741A patent/AU2001229741A1/en not_active Abandoned
- 2001-01-24 CA CA002398010A patent/CA2398010A1/en not_active Abandoned
- 2001-01-24 EP EP01942644A patent/EP1254179A4/en not_active Withdrawn
-
2003
- 2003-11-10 US US10/705,644 patent/US7419780B2/en not_active Expired - Fee Related
-
2008
- 2008-07-30 US US12/221,180 patent/US20100261167A1/en not_active Abandoned
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314817A (en) | 1988-11-18 | 1994-05-24 | The Regents Of The University Of California | Catalytic and reactive polypeptides and methods for their preparation and use |
US5468614A (en) | 1990-01-24 | 1995-11-21 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
EP0742015A1 (en) | 1990-11-06 | 1996-11-13 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
WO1996030540A2 (en) | 1995-03-20 | 1996-10-03 | The Regents Of The University Of California | Substrates for beta-lactamase and uses thereof |
US5736343A (en) | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
WO1997031113A1 (en) | 1996-02-23 | 1997-08-28 | Ariad Pharmaceuticals, Inc. | Cell-based assay |
US5928868A (en) | 1996-04-26 | 1999-07-27 | Massachusetts Institute Of Technology | Three hybrid screening assay |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
US6200759B1 (en) | 1996-08-23 | 2001-03-13 | President And Fellows Of Harvard College | Interaction trap assay, reagents and uses thereof |
WO1998013353A1 (en) | 1996-09-26 | 1998-04-02 | Aurora Biosciences Corporation | Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and use for cellular assays in drug discovery |
US6030785A (en) | 1997-03-05 | 2000-02-29 | University Of Washington | Screening methods to identify agents that selectively inhibit hepatitis C virus replication |
WO1999010510A2 (en) | 1997-08-26 | 1999-03-04 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
WO1999010508A1 (en) | 1997-08-27 | 1999-03-04 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
WO2002059272A2 (en) | 2001-01-24 | 2002-08-01 | The Trustees Of Columbia University In The City Of New York | Covalent chemical inducers of protein dimerization and their uses in high throughput binding screens |
US20020168685A1 (en) | 2001-01-24 | 2002-11-14 | Cornish Virginia W. | Covalent chemical inducers of protein dimerization and their uses in high throughput binding screens |
WO2003060073A2 (en) | 2001-12-21 | 2003-07-24 | The Trustees Of Columbia University In The City Of New York | An in vivo protein screen based on enzyme-assisted chemically induced dimerization ('cid') |
US20030138785A1 (en) | 2001-12-21 | 2003-07-24 | Stephan Kopytek | In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID") |
US20030203471A1 (en) | 2002-04-24 | 2003-10-30 | Althoff Eric A. | Bacterial small-molecule three-hybrid system |
WO2004042345A2 (en) | 2002-04-24 | 2004-05-21 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
US7083918B2 (en) | 2002-04-24 | 2006-08-01 | The Trustees Of Columbia University In The City Of New York | Bacterial small-molecule three-hybrid system |
Non-Patent Citations (50)
Title |
---|
Abida et al. (ChemBioChem, 2002, vol. 3, pp. 887-895). * |
Amara, J. F. et al. : A versatile synthetic dimerizer for the regulation of protein-protein interactions, Proc. Natl. Acad. Sci. USA, vol. 94, 1997, pp. 10618-10623. |
Austin DJ, et al. Proximity versus allostery: the role of regulated protein dimerization in biology. 1994. Chem Biol. 1(3): 131-6. |
Bacharach et al. (1998) Binding of Human Immunodeficiency Virus Type 1 Gag Protein to the Viral RNA Encapsidation Signal in the Yeast Three-Hybrid System, J. Virol. 72(8) :6944-6949. |
Belshaw PJ, et al. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. 1996. Chem. Biol. 3:731-738. |
Belshaw PJ, et al. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. 1996. Proc. Natl Acad Sci USA 93(10):4604-7. |
Choi J, et al. Structure of the FKBP-12-Rapamycin complex interacting with the binding domain of human FRAP. 1996. Science 273(5272):239-42. |
Cornish, Virginia W. et al., "Dexamethasone-Methotrexate: An Efficient Chemical Inducer Of Protein Dimerization In Vivo," Abstracts of Papers American Chemical Society, vol. 219, No. 1-2, p. BIOL 124 (2000). |
Cornish, Virginia W. et al., "Synthesis of Dexamethasone-Methotrexate CIDS With Variable Linkers," Book of Abstracts, American Chemical Society, 219<SUP>th </SUP>ACS National Meeting, San Francisco, CA, p. CHED 401 (Mar. 26-30, 2000). |
DeGrado WF, et al. Screening, selection and design: standing at the crossroads in three dimensions. 1997. Current Opinion in Structural Biology 7:455-456. |
Diver SR, et al. Single-step synthesis of cell-permeable protein dimerizers that activate signal transduction and gene expression. 1997. J. Am. Chem. Soc. 119: 5106-5109. |
Dove et al., (1997) "Activation of Prokaryotic Transcription Through Arbitrary Protein-Protein Contacts"Nature 386:627-630 ; and. |
Fan, J. et al. (1989) Covalent labeling of dihydrofolate reductase and folate transport proteins by fluorescein methotrexate, chemistry and biology of pteridines, 1990 Walter de Gruyter & Co., pp. 1162-1165. |
Filman et al., (1982) "Crystal Structures of Escherichia coli and Lactobacillus casei Dihydrofolate Reductase Refined at 1.7 A Resolution", The Journal of biological Chemistry 257(22): 13663-13672. |
Final Office Action issued Oct. 16, 2007 in connection with U.S. Appl. No. 10/056,874. |
Firestine, S.M., et al. Using an AraC-Based three-hybrid system to detect biocatalysts in vivo. 2000. Nature Biotechnology. 18, 544-547. |
Griffith, E.C. et al. "Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions," Methods in Enzymology, vol. 328, pp. 89-103 (2000). |
Ho SN, et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996. Nature. 382(6594):822-6. |
Holsinger LJ, et al. Signal transduction in T lymphocytes using a conditional allele of Sos. 1995. Proc. Natl. Acad. Sci. USA 92:9810-9814. |
Hung DT, et al. Understanding and controlling the cell cycle with natural products. 1996. Chem. Biol. 3:623-639. |
Klemm JD, et al. Dimerization as a regulatory mechanism in signal transduction. 1998. Annu. Rev. Immunol. 16:569-92. |
Kopytek, S.J., et al. Chemically Induced Dimerization of Dihydrofolate Reductase by a Homobifunctional Dimer of Methotrexate. 2000. Chem Biol. 7:313-321. |
Ladant, D., Karimova, G. Genetic systems for analyzing protein-protein interactions in bacteria. 2000. Res. Microbiol. 151, 711-720. |
Liberles SD, et al. Inducilble gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. 1997. Proc. Natl. Acad. Sci. USA 94(15):7825-7830. |
Licitra EJ, et al. A three-hybrid system for detecting small ligand-protein receptor interactions. 1996. Proc. Natl. Acad. Sci. USA 98:12817-12821. |
Lin et al. (2000) "Dexamethasone 21-mesylate: an efficient chemical inducer of protein dimerization in vivo" In vivo, J. Am. Chem. Soc., 122: Supplemental Information pp. S1-S12. |
Lin, H., et al. Dexamethasone-Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo. 2000. J.Am.Chem.Soc. 122:4247-4248. |
Notice of Allowance issued Nov. 13, 2007 in connection with U.S. Appl. No. 10/614,625. |
Office Action issued Oct. 1, 2007 in connection with U.S. Appl. No. 10/512,497. |
PCT International Search Report dated Jul. 17, 2003 corresponding to PCT International Application No. PCT/US02/40943. |
Pedersen H, et al. A method for directed evolution and functional cloning of enzymes. 1998. Proc. Natl. Acad. Sci. USA 95:10523-10528. |
Pelletier, J.N., et al. Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments. 1998. Proc.Natl.Acad.Sci.USA. 95, 12141-12146. |
Pollock et al. Demerizer-regulated gene expression. Current Opinion in Biotechnology (2002) 13:459-467. |
Pruschy MN, et al. Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. 1994. Cbem. Biol. 1:163-172. |
Schreiber SL. Chemical genetics resulting from a passion for synthetic organic chemistry. 1998. Bioorganic & Medicinal Chemistry 6:1127-1152. |
Search Report dated May 14, 2001 corresponding PCT International Application No. PCT/US01/02285. |
Sengupta et al. (1999) Identification of RNAs that bind to a Specific Protein Using the Yeast Three-Hybrid System, RNA 5:596-601. |
Simons, S. et al., (1981) Dexamethasone 21-mesylate: an affinity label of glucocorticoid receptors from rat hepatoma tissue culture cells, Biochemistry 78 (6) : 3541-3545. |
Spencer DM , et al. Controlling signal transduction with synthetic ligands. 1993. Science 262(5136):1019-1024. |
Spencer DM, et al. A general strategy for producing conditional alleles of Src-like tyrosine kinases. 1995. Proc. Natl. Acad. Sci. 92:9805-9809. |
Spencer DM, et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996. Curr Biol. 6(7):839-47. |
Stockwell BR, et al. Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers.1998. Curr Biol 8(13):761- 70. |
Stockwell BR, et al. TGF-beta-signaliung with small molecule FKBP12 antagonists that bind myristoylated FKBP12- TGF-beta type 1 receptor fusion proteins. 1998. Chem Biol. 5(7):385-95. |
Supplementary Partial European Search Report issued Apr. 19, 2005 in connection with the counterpart European Application No. 01942644.4. |
Van Criekinge et al. (1998) Use of the Three-Hybrid System as a Tool to Study Capsases, Anal. Biochem. 263(1). |
Vidal et al. (1999) Yeast Forward and Reverse 'n'-Hybrid Systems Nuc. Acid Res. 27(4) :919-929. |
Winkler T., et al. Confocal fluorescence coincidence analysis: An approach to ultra high-throughput screening. 1998 Proc. Natl. Acad. Sci. USA 96:1375-1378. |
Written Opinion, published Mar. 20, 2003, corresponding to PCT International Application Publication No. WO 02/059272 A3. |
Yang, J., et al. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. 1997 Curr. Biol. 8:11-18. |
Zlokarnik G, et al. Quatitation of tranmscription and clonal selection of single living cells with beta-lactamase as reporter. 1998, Science 279(5347):84-8. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100261167A1 (en) * | 2000-01-24 | 2010-10-14 | The Trustrees Of Columbia University In The City Of New York | In vivo screen using chemical inducers of dimerization |
US20090162858A1 (en) * | 2007-09-18 | 2009-06-25 | Cornish Virginia W | Orthogonal chemical inducer of dimerization |
Also Published As
Publication number | Publication date |
---|---|
US20020004202A1 (en) | 2002-01-10 |
US20100261167A1 (en) | 2010-10-14 |
CA2398010A1 (en) | 2001-07-26 |
AU2001229741A1 (en) | 2001-07-31 |
EP1254179A4 (en) | 2005-06-01 |
WO2001053355A1 (en) | 2001-07-26 |
US20040106154A1 (en) | 2004-06-03 |
EP1254179A1 (en) | 2002-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100261167A1 (en) | In vivo screen using chemical inducers of dimerization | |
US20020168737A1 (en) | Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization | |
US6183965B1 (en) | Synthetic transcriptional modulators and uses thereof | |
EP3046932B1 (en) | Evolved sortases and uses thereof | |
US9267127B2 (en) | Evolution of bond-forming enzymes | |
US8349619B2 (en) | Method for detecting and analyzing protein interactions in-vivo | |
US9290544B2 (en) | Methods for making and using molecular switches involving circular permutation | |
Sarmiento et al. | Biotechnological applications of protein splicing | |
Moore et al. | The development of β-lactamase as a highly versatile genetic reporter for eukaryotic cells | |
Cheriyan et al. | Protein splicing: a versatile tool for drug discovery | |
CA2312379A1 (en) | A bacterial multi-hybrid system and applications | |
US7083918B2 (en) | Bacterial small-molecule three-hybrid system | |
US20030138785A1 (en) | In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID") | |
McNabb et al. | Genetic and biochemical probes for protein—protein interactions | |
US20040053388A1 (en) | Detection of protein conformation using a split ubiquitin reporter system | |
JP2004516848A (en) | Modification targeting intracellular compounds | |
US20090162858A1 (en) | Orthogonal chemical inducer of dimerization | |
CZ2001273A3 (en) | Processes and preparations for determining function of proteins and identification of corresponding modulators | |
EP1349943A2 (en) | Detection of protein conformation using a split ubiquitin reporter system | |
US9970925B2 (en) | In vivo reporter system | |
US20070178460A1 (en) | Method for the identification of suitable fragmentation sites in a reporter protein | |
Lew | Harnessing inteins as a protein engineering tool | |
Silver et al. | The Identification of Novel Ligands for Cell Surface Receptors | |
KR20150017993A (en) | Sensor for protease activity assay using autoinhibitory protein, and method for measuring protease activity using the protease sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORNINGSIDE, COLUMBIA UNIVERSITY OF NY, NEW YORK Free format text: CONFIRMATORY LICENSE;ASSIGNOR:NATIONAL SCIENCE FOUNDATION;REEL/FRAME:020573/0922 Effective date: 20080130 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment |
Year of fee payment: 7 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20200902 |